

CURRICULUM VITAE

PERSONAL INFORMATION

Name: Paul Brent Watkins, M.D.

EDUCATION

Burnt Hills, Ballston Lake Senior High, 1968-1971

Cornell University, Ithaca, NY, 1971-1975

Degree: B.A.

Major: Physical Chemistry

Cornell Medical College, New York, NY 1975-1979

Degree: M.D.

POSTDOCTORAL TRAINING

Fellowship (Gastroenterology/Hepatology) 7/82 - 7/84

7/83-7/84 - Research Fellow

NIH Training Grant

Medical College of Virginia/

Division of Environmental Medicine and Clinical Toxicology

7/82-7/83 - Clinical Fellow

Medical College of Virginia/

McGuire Veterans Administration Medical Center

Residency (Internal Medicine)

The New York Hospital - Cornell Medical Center - 7/80-7/82

Internship (Internal Medicine)

The New York Hospital - Cornell Medical Center - 7/79 - 7/80

Special Experience

Admission Ward Physician - 4/82 - 7/82

Khao-I-Dang Cambodian Refugee Camp, Thailand

ACADEMIC APPOINTMENTS

University of North Carolina

Verne S. Caviness Distinguished Professor of Medicine – 8/1/99 – 7/1/11

Professor of Experimental Therapeutics (School of Pharmacy) - 8/1/99 – present

Professor of Toxicology (School of Public Health) – 5/1/07 – present

Director, General Clinical Research Center- 8/1/99 – 5/19/08

Director, Translational and Clinical Sciences Institute – 1/15/07 – 9/1/08

Director, Hamner – UNC Institute for Drug Safety Sciences 9/1/08 - present

University of Michigan

Professor of Pharmacology - 9/1/98- 7/31/99

University of Michigan (continued)

Professor of Medicine - 9/1/97 – 7/31/99
Director, General Clinical Research Center - 6/1/91 – 7/31/99
Associate Professor of Medicine - University of Michigan - 6/91 – 7/31/99
Associate Director, Clinical Research Center - 3/1/91 - 6/1/91
Assistant Professor of Medicine - University of Michigan - 8/86 - 6/91
Assistant Professor of Medicine - Medical College of Virginia - 7/85 - 7/86
Instructor - Department of Medicine - Medical College of Virginia - 7/84 - 7/86

FDA ACTIVITIES:

FDA consultant for *in vivo* Drug Metabolism Working Group 1997-99
FDA consultant for Liver Disease Working Group 1997-99
FDA consultant for Nonprescription Drugs Advisory Committee 9/19-20, 2002
FDA consultant for Cardiovascular Drugs Advisory Committee 9/10/04
Scientific Advisory Board - National Center for Toxicological Research, 2010 - present

SCIENTIFIC ACTIVITIES

Editorial Boards: Hepatology - 1/1/91 – 7/01/02
Drug Metabolism and Disposition - 1/1/94 – 98, 2002 - present
Pharmacogenetics - 1996 - present
Clinical Pharmacology and Therapeutics – 4/05 - present

Ad hoc reviewer for the Journal of Biological Chemistry, Hepatology, Journal of Clinical Nutrition, Journal of Clinical Investigation, Gastroenterology, Annals of Internal Medicine, Biochemical Pharmacology, New England Journal of Medicine, Molecular Pharmacology, British Journal of Clinical Pharmacology, Clinical Pharmacology and Therapeutics

Study Sections

National Institutes of Health, Toxicology I Study Section 10/92- 10/96

Ad hoc reviewer for GMA-2 Study section, National Institutes of Health - 6/91

GCRC "Special" site visit review team 4/13/01

Abstract Selection Committee - American Association for the Study of Liver Disease 10/91 – present; Chair Hepatotoxicity Section 10/09 – present

Abstract Selection Committee - American Gastroenterology Association 10/96-present; Chair Hepatotoxicity Section 10/09 – present

Finalist interview panel, 2006 NIH Director's Pioneer Awards. 8/16 – 8/18/06

Rapporteur (chairman), Mid-cycle review of 5 year, 40 million Euro SAFE-T Initiative supported by the European Union through the Innovative Medicines Initiative. This is a private public partnership to develop novel biomarkers of drug-induced injury to the liver, kidney and blood vessels. 4/1/11 – 12/1/11

SCIENTIFIC ACTIVITIES (Continued)

Advisory Boards

Advisory Committee for Johnson & Johnson's
\$30,000,000 grant to the Dermatology Department 1992- 1999
University of Michigan Cardiovascular Research Center Exec. Committee 1991-96
Board of Directors, The GCRC National Directors Association 1992-96
Advisory Board, Michigan Psychiatric Research Center 1992 – 94
Chairman, GCRC Directors Annual National Meeting 12/94, Reston, VA.
Ad Hoc Advisory Committee, Bionutrition Initiative, National Institute of
Health 1993-94
National Resources Council/National Academy of Sciences Committee on
Comparative Toxicity of Naturally Occurring Carcinogens 1993-95
Chairman, Advisory Board for Multicenter Cognex Rechallenge Study 1994-1996
Board of Directors, Metabolic Solutions Inc. Merrimack, NH 1994 - present
Chairman, Scientific Advisory Board, Avmax Inc., San Francisco, CA 1995 -
2004
Dean's Advisory Committee on Gene Therapy 1995 - 1996
Health Advisory Board, Ecology and Environment, Buffalo N.Y.
9/97 – 1/00
Scientific Advisory Committee for International Society for the Study of
Xenobiotics annual meeting in Nashville Tennessee, 10/99.
Chairman, Scientific Advisory Committee for Symposium on Drug Induced Liver
Disease, Chicago, IL. 10/12 - 10/14/98
Abbott-Genset Scientific Advisory Board 1998 - 2000
Roche/Tasmar Safety Advisory board 1998 – 1999
FDA/Pharma Hepatotoxicity Steering Committee 1999 – present
Smith Kline Beecham Research and Development Advisory Board 1999 -2000
Program Committee for International Society for the Study of
Xenobiotics annual meeting in Indianapolis, Indiana 10/00

SCIENTIFIC ACTIVITIES (Continued)

International Life Sciences Institute's Task Force on Non-Clinical/Clinical Safety Correlations 1999-present

Faculty Advisory Committee, University of North Carolina's Environmental Program 2000 – 2008

Chairman, Advisory Committee for the Research Triangle Park Drug Metabolism Discussion Group 9/00 – 8/01

Chairman, General Clinical Research Center National Task Force on Industry Research 8/00 – 8/01

GlaxoSmithKline Research and Development Advisory Board 2000 – 2009

Steering Committee - National Institute of Environmental Health Sciences Environmental Polymorphism Study (EPS) 6/01/02 – present

Steering Committee – National Institute of General Medical Sciences Pharmacogenomics Network 11/01/02 – 12/31/03.

Steering Committee – United Arab Agencies, Saudi Public Health Monitoring and Assessment Claim Studies Project; \$19 million grant to Johns Hopkins School of Public Health 6/01/03 – 5/31/06

Chairman, Steering Committee – National Institutes of Diabetes, Digestive and Kidney Diseases Drug Induced Liver Injury Network 7/1/03- present

Member, Executive Committee – National Institutes of Diabetes, Digestive and Kidney Diseases Drug Induced Liver Injury Network 7/1/03- present

Invited participant, National Center for Research Resources Strategic Planning Forum
“Choices and Challenges: Future Directions for the NCRR”
9/10-11/03

Committee member - Action Plan for Liver Disease Research - National Institutes of Diabetes, Digestive and Kidney Diseases. 2/04 – present

External Advisory Committee – Research Center in Minority Institution (RCMI), University of San Juan Puerto Rico 6/03 – 6/10

Invited participant - National Institutes of Environmental Health Sciences Environmental Genomics Workshop to Consider Future Directions of Genomics Research. 6/28-29/05

Chairman, FDA Scientific Advisory Committee for the Liver Toxicology Biomarker Study of the Food and Drug Administration's Critical Path Initiative 12/01/05 – 7/1/10

External Ad Board, Vanderbilt Center in Molecular Toxicology, 11/15/05 – present

SCIENTIFIC ACTIVITIES (Continued)

- Scientific Management Committee, International Severe Adverse Events Consortium 7/07 - present
- FDA Clinical Pharmacology Advisory Committee, Ad Hoc member 10/06 – present
- Member, NIH Director’s Pioneer Award Finalist Interviewer Panel 8/7-9/06
- Hamner Institute – Scientific Advisory Board 3/07 – present
- Chairman, Scientific Advisory Committee for the Virtual Liver Project of the Food and Drug Administration’s Critical Path Initiative 11/08 – 7/1/10
- Chairman, Genetics Committee – National Institutes of Diabetes, Digestive and Kidney Diseases
Drug Induced Liver Injury Network 1/09 – present
- External Advisory Committee – Centre for Drug Safety Sciences, University of Liverpool, UK 7/09 – present
- Advisory Committee – International Drug Induced Liver Injury Consortium – 11-09 - present
- External Advisory Committee for the Clinical and Translational Science Institute at the University of Michigan 9/09 – 12/11
- Chairman, Hepatotoxicity Special Interest Group, American Association for the Study of Liver Diseases 11-09 – present
- FDA Scientific Advisory Board Subcommittee on Pharmacovigilance 6/10 – 7/11
- Founding member, International Society for Translational Medicine - 2010 - present
- Scientific Liaison Task Force, Society of Toxicology - 2010 – present
- FDA Scientific Advisory Board of the National Center for Toxicological Research, 2010 - present
- North Carolina Institute for Rare, Orphan and Neglected Diseases (IRON) – Member of Steering Committee, 2011- present
- Member, Committee on Translational Imaging, Health and Environmental Sciences Institute (HESI), Washington, DC, 2012 – present
- Member, Scientific Advisory Board – Innovative Medicines Initiative Joint Undertaking (IMI JU): “Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury; MIP-DILI”- 2012 – present
- Member, Advisory Committee of the Burroughs Wellcome Fund’s new initiative “Innovation in Regulatory Science” – 2012 – present

PATENTS

1. Patent Number: 5,100,779
Date of Patent: 3/31/92
Title: Method for Determining Function of a Unique Cytochrome P-450 Activity
2. Patent Number: 5,856,189
Date of Patent: 1/5/99
Title: Cell Culture Model for Drug Bioavailability

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS

1. 4/6/82 The American Society for Microbiology
(PLENARY SESSION, Annual Meeting, New York City Branch)
Topic: Paralysis in a Drug Addict
2. 5/19/85 American Gastroenterology Association
(RESEARCH PLENARY), American Association for the Study of Liver Disease,
New York, NY)
Topic: Identification of a Dexamethasone Inducible Isozyme of Cytochrome P-450 in Rat and Human Intestine
3. 8/20/85 American Society for Pharmacology and Experimental Therapeutics
(RESEARCH SYMPOSIUM, Annual Meeting, Boston, MA)
Topic: Human Liver Cytochromes P-450
4. 10/27/87 American Association for the Study of Liver Diseases
(PLENARY SESSION, Chicago, New York)
Topic: Erythromycin Breath Test
5. 10/11/88 American Society of Pharmacology and Experimental Therapeutics
(RESEARCH PLENARY, Montreal, Canada)
Topic: The Nitrosodimethyl Amine Breath Test
6. 7/9/89 Gordon Conference on Pharmacology and Toxicology
(PLENARY SESSION, Plymouth, NH)
Topic: Noninvasive Assays of Cytochromes P-450 in Rats and patients
7. 6/25/90 VIIIth International Symposium on Microsomes and Drug Oxidations
(RESEARCH SYMPOSIUM, Stockholm, Sweden)
Topic: In Vivo/ in Vitro Characterization of Cytochrome P450III_A. Implications for the Use of Cyclosporine and Calcium Channel Blockers
8. 11/5/90 American Association of Pharmaceutical Scientists Annual Meeting
(RESEARCH SYMPOSIUM, Las Vegas, NV)
Topic: The Erythromycin Breath Test
9. 7/14/92 Gordon Conference on Drug Metabolism
(PLENARY SESSION, Plymouth, NH) Topic: First Pass Metabolism of Drugs by P450III_A in Gut

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

10. 7/14/92 Gordon Conference on Drug Metabolism
Plymouth, NH
Discussant: Session Entitled "Noninvasive Tests of P450s in Patients"
11. 10/31/92 American Association for the Study of Liver Diseases Annual Meeting
(RESEARCH WORKSHOP, Chicago, IL)
Topic: Noninvasive Measurements of Human Cytochromes
12. 11/2/92 International Society for the Study of Xenobiotics - Annual Meeting
(SHORT COURSE, Miami, FL)
Topic: In Vivo Studies of Human P450s - Effect on Pharmacokinetic
13. 11/16/92 Association of American Pharmaceutical Scientists Annual Meeting
San Antonio, TX
(PPDM/MNPC Joint Symposium: In vitro/In Vivo Correlation in Hepatic P450-Mediated Drug Metabolism)
Topic: Clinical Significance of Inter-patient Differences in Cytochrome P450III A Activity.
14. 1/25/93 Institute of Medicine Forum on Drug Development
Washington DC
Workshop entitled "Enzymes of Drug Metabolism: Importance to Drug Safety and Efficacy."
Topic: Metabolism in the Gut.
15. 5/23/94 FDA Symposium
Washington, DC
Topic: Women in Clinical Trials
16. 7/8/94 14th European Workshop on Drug Metabolism
Paris, France
Topic: Intestinal Metabolism
17. 7/20/94 International Meeting on Microsomes and Drug Oxidations
Toronto, Canada
Topic: CYP3A enzymes in human intestine
18. 11/14/94 American Association for the Study of Liver Diseases
Chicago, IL
Early Morning Workshop, Co-Chairman
Topic: Drug Induced Liver Disease
19. 2/13/95 Drug Information Association
Toronto, Canada
Symposium: Understanding drug interactions
Topic: The role of P4503A4 in drug interactions.

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

20. 3/7/95 Society of Toxicology Annual Meeting
Baltimore, MD
Symposium: "The toxicological implications of microsomal induction in the development of novel compounds"
Topic: Implication of induction of CYP1A2 And CYP3A4 in drug interactions and susceptibility to environmental disease.
21. 4/15/95 American Society for Experimental Therapeutics Annual Meeting
Atlanta, GA
Symposium: "Validation and application of noninvasive probes of human CYP3A"
Topic: Clinical Applications of the erythromycin breath test.
22. 7/11/95 Annual United Kingdom Drug Metabolism Group Meeting
Nottingham, England
Plenary Talk: Noninvasive probes of CYP3A enzymes: Problems and Prospects
23. 11/13/95 1st International Symposium on Drug interactions
St. Louis, MO
Plenary "State of the Art" Lecture
Topic: The clinical significance of drug interactions
24. 9/5/95 10th International Symposium on Therapeutic Drug Monitoring
Vienna, Austria
Symposium: Use of Liver Function Tests in Transplantation
Topic: The use of the erythromycin breath test in transplantation.
25. 11/20/95 American Association of Pharmaceutical Scientists
San Diego, CA
Invited talk: Use of ketoconazole to inhibit taxol metabolism in patients In vitro in
26. 8/9/96 - Vth International Congress on Clinical Pharmacology
Buenos Aires, Argentina
Symposium: Drug interactions involving CYP3A4 and CYP1A2
Topic: Understanding drug interactions involving CYP3A4
27. 5/27/96 - International Business Conference on Pharmacogenetics
Washington, DC
Topic: Use of the erythromycin breath test in drug development
28. 7/30/96 - Eighth Japanese American Forum of Drug Metabolism
Seattle, WA
Symposia: Optimum delivery of biologic and xenobiotic drugs
Topic: MDR1 transport protein and P450 enzymes as barriers to oral drug availability.
29. 4/26/96 - American College of Physicians Annual Meeting
San Francisco, CA
Symposium: Drug Induced Liver Disease
Topic: The role of cytochromes P450 in drug induced liver disease

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

30. 10/23/96 - International Society for the Study of Xenobiotics
San Diego, CA
Symposium: Enzyme Induction
Topic: The effects of diet and medications on regulation of CYP3A4 and MDR1 in human intestine.
31. 12/10/96 - International Business Conference on Drug Interactions
Bethesda, MD
Topic: The mechanistic basis for the grapefruit juice effect.
32. 3/9/97 - American Society for Clinical Pharmacology and Therapeutics Annual Meeting
San Diego, CA
Symposium: The intestinal barrier
Topic: The role of CYP3A4 in limiting the oral availability of drugs.
33. 4/7/97 - Third Annual International Business Conference on Pharmacogenetics
Washington, DC
Program Chairman
Invited talk: CYP3A4, P-glycoprotein, and oral availability of drugs
34. 4/10/97 - Food and Drug Administration
Silver Spring, MD
Invited Talk: The Emerging Role of CYP3A4 and P-glycoprotein in determining drug bioavailability
35. 5/16/97 - The Impact of Pharmacokinetics in Modern Drug Development
San Francisco, CA.
Invited talk: A Human study supporting the role of intestinal p-glycoprotein in limiting the oral availability of drugs
36. 7/17/97 - International Business Conference - Drug-Drug interaction
London, England
Invited Talk: Understanding Drug Interactions Involving CYP3A4
37. 7/7/97 - Gordon Conference on Drug Metabolism
Plymouth, NH
Discussion Leader, Session on Clinical Relevance of Drug Interactions
Invited talk: Clinical Relevance of Drug Interactions Involving CYP3A4
38. 7/9/97 - Gordon Conference on Drug Metabolism
Plymouth, NH
Invited Talk: Applications of noninvasive tests of CYP3A4
39. 7/13/97 - International Business Conference on Drug Interactions
London, England
Invited Talk: Understanding drug interactions involving CYP3A4

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

40. 11/7/97 American Association for the Study of Liver Diseases Annual Meeting
Chicago, IL
Postgraduate Course "Liver Injury Update: Clinical implications of mechanistic role of cells of the liver"
Invited presentation: The cytochromes P450: implications in prevention and treatment of drug-induced liver disease.
41. 12/15/97 - International Business Conference on Drug Interactions
Washington, DC
Invited Talk: Use of probe substrates in clinical trials
42. 1/20/98 - American Association of Pharmaceutical Scientists Frontier Symposium
Bethesda, MD
Invited talk: Clinical Aspects of Cytochrome P450 Induction
43. 3/1/98 - American Academy of Dermatology Annual Meeting
Orlando, FL
Invited talk: The role of cytochromes P450 in drug interactions
44. 7/22/98 12th International Symposium on Microsomes and Drug Oxidations
Montpellier, France
Invited Plenary Session Talk
Extrahepatic Distribution and Role of CYP3A Enzymes
45. 9/18/98 - International Congress of Clinical Applications of Breath Tests in Gastroenterology and Hepatology
Rome, Italy
Invited Talk: The erythromycin breath test
46. 10/7/98 - Esteve foundation Symposium VIII: Variability in human drug response
Stiges, Spain
Invited Talk: Transporters: Pharmacokinetic/pharmacodynamic/therapeutic and toxicological impact.
47. 10/12/98 - Symposium on Drug Induced Liver Disease; Co-chairman
Chicago, IL
Invited Talk: Role of bioactivation enzymes
48. 11/8/98 American College of Clinical Pharmacy Annual Meeting
Cincinnati, OH
Therapeutic Frontiers Award and Plenary Lecture
The role CYP3A4 and P-glycoprotein in controlling systemic availability of orally administered drugs.
49. 8/10/99 International Symposium "Membrane Transporters: New Perspectives in Drug Delivery and Drug Targeting,
Ascona, Switzerland
10/26/99 Plenary talk: The basis and consequences of variable MDR1 expression

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

50. 9/13/99 Barnett International Symposium on Drug-Drug Interaction
Washington, DC
Chairman of entire meeting
Invited Talk "Use of the Erythromycin Breath test in Predicting CYP3A4 Drug Interactions"
51. 11/7/99 Annual Meeting of the American Association for the Study of Liver Diseases
Dallas, TX
Meet the Professor Breakfast: Update on Drug Induced Liver Disease
52. 11/13/99 International Society for the Study of Xenobiotics Annual Meeting
Nashville, TN
Invited Talk: Extrahepatic drug metabolism
53. 4/17/00 Millennium World Congress on Pharmaceutical Sciences
San Francisco, CA
Invited Talk: Clinical aspects of drug transporters
54. 6/12/00 International Society for the Study of Xenobiotics
Drug Metabolism Workshop
Dundee, Scotland
Invited talk: Role of transporters in drug disposition
55. 6/19/00 IV International Symposium on Drug Interactions
Baltimore, MD
Invited talk: Citrus juices and transporters in the small bowel
56. 7/16/00 International Microsomes and Drug Oxidations Symposium
Stresa, Italy
Chairman, Session entitled "Extrahepatic Metabolism"
57. 10/17/00 Drug Information Agency's Symposium on Biomarkers
Arlington, VA
Invited talk: Use of Biomarkers in Assessing Drug-induced Liver Disease in Clinical Trials
58. 10/28/00 Annual Meeting of the American Association for the Study of Liver Diseases
Dallas, TX
Meet the Professor Breakfast: Update on Drug Induced Liver Disease
59. 11/14/00 – European Society for Clinical Pharmacology
Basel, Switzerland
Invited Talk: Diet/Drug Interactions
60. 11/3/00 Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Meet the Professor Luncheon: Pharmacogenetics and Drug Induced Liver Injury

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

61. 2/13/01 – FDA/Pharma Symposium on Drug Induced Liver Injury
Rockville, MD
Invited Talk: Pharmacogenetic/Pharmacogenomic approaches
62. 3/7/01 – American Society for Clinical Pharmacology and Therapeutics
Orlando, FL
Invited talk: Drug Interactions with Herbal Products and Foods
63. 7/10/01 – Toxicology Forum
Aspen, CO
Invited talk: Mechanism of Drug Induced Liver Disease
64. 9/17/01 The Benzoin Symposium No.48
Drug Metabolism: Regulation and Importance
Copenhagen, Denmark
Invited Talk: Probe based tests of CYP3A enzymes
65. 10/10/01 – International Society for the study of Xenobiotics
Munich, Germany
Invited Talk: Role of Transporters in Oral Availability
66. 2/06/02 – Toxicology Forum
Washington, DC
Invited talk: Mechanism-based inactivation by fruit juices
67. 5/30/02 – Centers for Education and Research in Therapeutics Annual Meeting
Chapel Hill, NC
Invited Talk: Pharmacogenomics and Adverse Events
68. 7/22/02 – American Society of Pharmacology and Therapeutics
Washington, DC
Invited Talk: Citrus juice / drug interactions
68. 11/2/02 - Annual Meeting of the American Association for the Study of Liver
Diseases
Boston, MA
Meet the Professor Luncheon: Pharmacogenetics and Drug Induced Liver Injury
69. 11/2/02 – Annual Meeting, American Association for the Study of Liver Diseases
Boston, MA
Meet the Professor Breakfast: Mechanisms of Drug Induced Liver Injury
70. 2/28/03 – Symposium on Drug Induced Liver Disease
Washington DC
Invited Talk: Clinical Research Methods for Identification of Susceptibility Factors
for Drug Induced Liver Disease
71. 7/14/03 – International Food Technology meeting
Chicago, IL
Invited talk: The Role of Furocoumarins in Grapefruit juice: drug Interactions

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

72. 5/6/03 – Tools for Pre-Approval Drug Safety
Rockville, MD
FDA course for medical reviewers
Invited talk: Hepatotoxicity and Drug Safety Evaluation
73. 10/13/03 – Clinical Investigation Student Training Forum
National Institutes of Health – 50th Anniversary celebration of the Clinical Center
Invited talk and round table discussion: “How to be a successful academician”
74. 10/25/03 - Annual Meeting of the American Association for the Study of Liver Diseases - Post Graduate Course
Boston, MA
Meet the Professor Luncheon: Drug Induced Liver Disease: Rezulin, Duract, Trovan and others
75. 10/5/03 - Annual Meeting of the American Association for the Study of Liver Diseases - Post Graduate Course
Boston, MA
Co-chair: Course session entitled “Drug Induced Liver Disease Liver”
76. 10/26/03 - Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Meet the Professor Luncheon: Mechanisms of Drug Induced Liver Disease
77. 10/25/03 - Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Co-moderator: Symposium on Toxicity and Drug Metabolism
78. 2/23-24/03 – Co-Chair Symposium on Drug Induced Liver Disease
Washington DC
Invited Talk: Pharmacogenomic Approaches
79. 6/14/04 – Annual meeting of The Society of Toxicologic Pathology
Salt Lake City, UT
Key Note Address: Drug Induced Liver Disease – A Clinician’s Perspective
80. 6/21/04 - 2004 Pharmacogenomics Conference
Nashville TN
Invited Talk: Genomic Approaches to Understanding Drug Induced Liver Disease
81. 7/13/03 – Drug Metabolism Gordon Conference
Holderness, NH
Discussion Leader: Clinical Aspects of Hepatotoxicity
Invited Speaker: Acute hepatocellular injury due to drugs
82. 8/30/04 - International Society for the Study of Xenobiotics Meeting
Vancouver, British Columbia
Invited talk: CYP3A4 and P-gp in the disposition of drugs: Clinical studies

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

83. 11/9/04 – Sixth International Workshop on the Pharmacodynamics of Anti-Cancer Agents
Venice, Italy
Invited talk: Metabolism in the Gut
84. 10/30/04 - Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Meet the Professor Luncheon: Drug induced transaminitis.
85. 10/31/04 - Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Breakfast workshop: Mechanisms of Drug Induced Liver Disease
86. 11/1/04 - Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA
Symposium entitled “CYPs and liver diseases
Invited Talk – CYPs and Drug Induced Liver Injury”
87. 11/1/04 – Annual meeting of The American Association for the Study of Liver Diseases
Boston MA
The Hyman Zimmerman State-of-the-Art Lecture
Topic: Hepatocellular injury caused by drugs and what’s being done about it.
88. 4/28/05 –Annual Clinical Research Meetings
Washington DC
“State of the Art” Plenary Lecture
Topic: Drug Induced Liver Injury – Breaking the promise of genomics to drug development
89. 6/5/05 – Gordon Conference on Adverse Drug Reactions
Chairman of session entitled “Drug-Induced Liver Injury
Invited speaker: Approaches to study Drug-Induced Liver Injury in humans
90. 8/24/05 – The International Society for Pharmacoepidemiology
Nashville TN
Invited speaker
Topic: The Drug Induced Liver Injury Network (DILIN)
91. 9/16 – 9/18/05 –Single Topic Conference on Drug Induced Liver Injury sponsored by the American Association for the Study of Liver Diseases
Atlanta, GA Co-Chair of Conference
Also Invited speaker: Mechanisms underlying adaptation to Drug-Induced Liver Injury.
92. 9/29/05 – 9/30/05 - IBC Conference on Signal Detection and Risk Assessment
Washington, DC
Invited Speaker: Update on The Drug Induced Liver Injury Network (DILIN)

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

93. 10/31/05 – 11/1/05 – NIEHS Center Directors Meeting,
Vanderbilt TN
Member Panel Discussion: “P30 Clinical Research in Environmental Health Sciences”
94. 12/01/05 - NIEHS Extramural Administrators Workshop
Wilmington, NC
Key Note Address: “Human Experimentation in Environmental Health Research”
95. 8/15/06 – NIH Roadmap meeting on Predictive Models for Drug Safety
Assessment
NIH Campus, Lister Auditorium
Key Note Address: “Idiosyncratic hepatotoxicity: Why current animal preclinical models fail?”
96. 12/11/06 – NIGMS workshop: Understanding the genetic basis of medication
safety
Bethesda, MD
Invited speaker – Idiosyncratic drug induced liver injury
97. 6/6/07 – New England Drug Metabolism Discussion Group
Boston, MA
Dinner Speaker: Hepatotoxicity: Why preclinical models fail
98. 3/26-3/27/08 - FDA/Pharma/AASLD workshop: Detecting and Investigating
Drug-Induced Liver Injury During Clinical Trials
Silver Spring, MD
Moderator: Session morning session entitled: “When to stop treatment with an
investigational drug”
99. 4/9/08 – 9th International Workshop on Clinical Pharmacology of HIV Therapy.
New Orleans, LA
Invited Plenary Talk: “Mechanisms underlying drug-induced liver injury: An
update.
100. 10/24/08 – Institute of Medicine Workshop on Biomarkers for Drug Safety
Washington, DC
Invited Presentation: Hepatotoxicity Biomarker White Paper
Co-chair, Hepatotoxicity Biomarkers Discussion Session
101. 10/28/08 – HESI Case Studies Workshop: Genomics Applications in Safety
Studies - Case Study Workshop
Washington DC
Invited talk: Use on genomics to identify hepatotoxicity biomarkers in clinical
trials: A case study in acetaminophen treated health volunteers
102. 11/1/08 : Annual meeting of the American Association for the Study of Liver
Diseases
San Francisco, CA
Breakfast workshop: Drug Induced Liver Disease.

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

103. 11/6-11/7/08 – CBI Symposium on Hepatotoxicity
Philadelphia, PA
Co-chair of Conference
Invited Speaker: Use of clinical trials to identify novel biomarkers of hepatotoxicity
104. 12/1/08 – NIH Conference on Nomenclature in Drug Induced Liver Injury
Bethesda, MD
Invited talk: Development of biomarkers for liver safety
Chair of afternoon session
105. 12/9/08 – New York Academy of Sciences symposium on Drug Safety
New York, NY
Invited talk: Novel approaches to understanding drug induced liver injury
106. 1/16/09 – National Center for Toxicologic Research
Little Rock, AR
Invited talk: Novel approaches to study acetaminophen toxicity
107. 1/25/09 – Molecular Medicine Tri-Conference
San Francisco, CA
Invited Talk: Novel preclinical approaches to predict drug induced liver injury
Session chairman.
108. 3/20/09 – American Society for Clinical Pharmacology and Therapeutics
Washington DC
Invited Talk: Translational research approaches to improve drug safety
109. 4/8/09 – FDA/Pharma/AASLD Hepatotoxicity Symposium
Silver Spring, MD
Invited talk: Update on the IOM and DILIN research agendas
Session Chairman
110. 5/31/09 – American Gastroenterology Association Annual meeting
Chicago, IL
Invited speaker at annual course: Drug Induced Liver Injury
111. 6/23/09 – Drug Information Association Annual Meeting
San Diego, CA
Invited talk: The Institute of Medicine report of biomarkers for drug safety
112. 6/30/09 – Center for Drug Safety Sciences Inaugural Symposium
Liverpool, England
Invited talk: Biomarkers for Drug Induced Liver Injury
113. 2/26/10 – FDA Institute of Medicine, Forum on Drug Discovery, Development and Translation
Washington, DC
Invited talk: The Hamner-UNC Institute for Drug Safety Sciences

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

114. 3/4/10 – Research Triangle Park Drug Metabolism Discussion Group - Winter Symposium
Research Triangle Park, NC
Plenary talk: Impact of Drug Metabolism Science in the 21st Century
115. 3/10/10 - Annual meeting of the Society of Toxicology
Salt Lake City, UT
Invited speaker: Novel Research Approaches and Animal Models in Translational Toxicology
116. 3/16/10 – Serious Adverse Event Consortium Phenotyping Standardization Project Consensus Conference
Hinnton, Cambridge, UK
Co-Chair: DILI Expert Working Group
117. 3/25/10 – Annual meeting of the American Association for the Study of Liver Diseases, Drug-Induced Liver Injury: Getting the Medicine and Science Together
Silver Spring, MD
Moderator of morning session IIIA: The Hamner Institute for DILI Research Programs
Invited speaker: Plans and Progress of the Hamner Programs
118. 4/26/10 – 2010 Economic Development Summit on Seizing Economic Opportunity through the Botanical Medicine and Integrative Health Industry
Asheville, NC
Invited speaker: Safety of Natural Products: A Competitive Advantage for North Carolina
119. 5/15/10 - Tuberculosis Trials Consortium (TBTC) Semi-Annual Group Meeting
New Orleans, LA
Invited Speaker: TB and hepatotoxicity: A great opportunity for biomarker discovery
120. 5/22/10 – 2010 Bio-X International Translational Medicine Symposium
Shanghai, China
Invited Speaker: Predicting and understanding drug-induced liver injury: an emerging role for personalized medicine
120. 6/8/10 – Delaware Valley Drug Metabolism Discussion Group Rozman Symposium
Langhorne, PA
Invited Speaker: Why Good Drugs are Sometimes Bad for the Liver
121. 6/16/10 – World Pharmaceutical Congress Fourth Annual Monitoring Cardiotoxicity and Drug Safety
Philadelphia, PA
Invited member of expert panel: Casting the Right Safety Net: Exploring Creative Options for Predicting Drug Safety
Invited Plenary Talk: New approaches to understand idiosyncratic hepatotoxicity

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

122. 9/5/10 – International Society for the Study of Xenobiotics 9th International Meeting
Istanbul, Turkey
Invited Speaker: Understanding Idiosyncratic Hepatotoxicity: From Man to Mouse to Computer

123. 11/8/10 – Mitigating Safety Risks in Early Clinical Development & Post-Approval Drug Development
Philadelphia, PA
Invited moderator of breakout discussion group: How to Minimize the Risk of Drug-Induced Liver Injury

124. 11/9/10 - Mitigating Safety Risks in Early Clinical Development & Post-Approval Drug Development
Philadelphia, PA
Invited Speaker: Idiosyncratic Liver Injury: Challenges and Approaches

125. 12/16/10 – Liver Toxicity Biomarker Workshop at the FDA
Silver Spring, MD
Invited Speaker: Liver Toxicity Biomarkers: Current state of the field and novel areas of research

126. 2/27/11 – Liver Disease Day
Indian Wells, CA
Invited Speaker: Why good drugs can be bad for the liver

127. 3/7/11 – Defense Threat Reduction Agency, Chemical and Biological Technologies Directorate All Hands Meeting
Dr. Belvoir, VA
Invited Speaker: Importance of Drug Safety to Defense Threat Reduction

128. 3/23/11 – AASLD/FDA/PhRMA Meeting: hepatotoxicity Special Interest Group: Drug Induced Liver Injury: Are we ready to Look?
Silver Spring, MD
Meeting Advisor and Session Speaker: Studies in Healthy Subjects Exposed to Drugs

129. 4/13/11 – ASPET 2011 Annual Meeting, part of the Experimental Biology 2011 Annual Meeting
Session Title: Pharmacogenomics to Address Adverse Drug Events
Washington, DC
Invited Speaker: Understanding Idiosyncratic Drug-Induced Liver Injury

130. 5/9/11 – AGA: Digestive Disease Week 2011
Chicago, IL
Invited State-of-the-Art Lecture: When Good Drugs are bad for the Liver

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

131. 5/15/11 – American Thoracic Society Annual Meeting
Denver, CO
Invited Speaker: Idiosyncratic Hepatotoxicity
132. 6/8/11 – World Pharma Congress: New Assays and Tools for Predicting
Hepatotoxicity
Philadelphia, PA
Invited Speaker: Mechanistic Insights into Hepatotoxicity
133. 8/16/11 – 27th International Conference on Pharmacoepidemiology & Therapeutic
Risk Management
Chicago, IL
Invited Speaker in Concurrent Symposium: Drug - Induced Liver Injury: Latest
Developments on Premarket Regulatory Guidance and Approaches to
Postmarket Surveillance
134. 8/30/11 – 242nd American Chemical Society National Meeting
Denver, CO
Invited Speaker: Idiosyncratic Drug Induced Liver Injury: From Man to Mouse to
Computer
135. 9/22/11 – Research Triangle Park Platform Technology and Science Discovery
Science Day
Research Triangle Park, NC
Invited Plenary Speaker: Translation, Integration and Investigation: The Path to
Discovering Safer Medicines
136. 10/4/11 - Tox 21 Symposium at the New York Academy of Sciences
New York, NY
Invited speaker: Idiosyncratic Hepatotoxicity: From Man to Mouse to Computer
137. 10/17/11 – Acute Liver Failure Study Group - Pathogenesis of Liver Injury Forum
Dallas, TX
Invited Speaker: GWAS Studies in DILIN
138. 10/26/11 – FDA/CDER Seminar Series
Silver Springs, MD
Invited Speaker: Why Good Drugs are Sometimes Bad for the Liver
139. 11/5/11 – AASLD The Liver Meeting 2011
San Francisco, CA
Invited Speaker: Drug-induced Liver Injury
Special Interest Group Program: The Role of Adaptive Immunity in DILI
140. 1/26/11 – National Institutes for Health
Research Triangle Park, NC
Invited Speaker: Recent Advances in understanding Idiosyncratic Hepatotoxicity

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

141. 2/17/12 – 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
Taipei, China
Invited Speaker: State of the Art Plenary Lecture: The US Drug Induced Liver Injury Network
142. 2/17/12 – 22nd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2012)
Taipei, China
Invited Speaker: Recent advances in biomarkers for the diagnosis and management of drug-induced liver injury
143. 3/14/12 - FDA DILI Conference - Why DILI Idiosyncrasy? The Immune System and Beyond...Why do only a few people show serious liver dysfunction from drugs that nearly everybody else can tolerate or adapt to?
Silver Spring, MD
Invited Presenter/Moderator: How and why do people respond differently to the same drug?
144. 4/3/12 – 4/4/12 – European Partnership for Alternative Approaches to Animal Testing (EPAA) Computational Chemistry Workshop “Revolutionizing Toxicology: Developing a research prospectus”
Brussels, Belgium
Invited Participant in workshop
145. 6/6/12 – World Pharma Congress Fourth Annual Tackling Drug-induced Idiosyncratic Hepatotoxicity
Philadelphia, PA
Keynote Speaker: Safety in Numbers: Exploring the Pre-Competitive Space
147. 6/9/12 – AASLD Clinical Research Single Topic Conference
Atlanta, Georgia
Course Director and Speaker: Acetaminophen Poisoning: Novel Biomarker Discovery in Healthy Volunteers and Patients with Acetaminophen Toxicity
Invited Speaker: Insights into the Management of Acetaminophen Poisoning from DILIsym- An *In Silico* Model of the Liver
148. 6/21/12 - International Society for the Study of Xenobiotics, European Annual Meeting
Grand Hotel Huis ter Duin
Netherlands
Invited Speaker: Using Inbred Mice to identify mechanisms underlying adverse drug events
Co-Chair: Symposium Adverse drug reactions: focus on mechanisms: Using Inbred mice to identify ADR mechanisms

INVITED TALKS AND NATIONAL AND INTERNATIONAL MEETINGS. Cont.

149. 6/27/12 - Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM)
Shanghai, China
Participant Round Table Discussion: Setting up translational medicine centers in China
150. 6/28/12 – Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM)
Shanghai, China
Invited Speaker: Drug Induced Liver Injury
151. 6/30/12 – 7th Shanghai Jiao Tong University Conference on Current Focus of Diabetes: New Technologies for Diabetes - from bench to bedside
Shanghai, China
Invited Speaker: The Problem of Hepatotoxicity in Diabetic Drug Development: The Legacy of Troglitazone”
152. 9/15/12 – Sino-American Symposium on Clinical and Translational Medicine
Satellite Workshop
Shanghai, China
Invited panelist with the Chinese SFDA, FDA and drug-induced liver injury experts to discuss DILI with the drug development and pre/post-market drug survey
153. 9/16/12 - Sino-American Symposium on Clinical and Translational Medicine
Satellite Workshop
Shanghai, China
Invited Plenary Speaker: First Eight Years of the U.S. Drug-Induced Liver Injury Network
154. 9/16/12 – Sino-American Symposium on Clinical and Translational Medicine
Satellite Workshop
Shanghai, China
Invited panelist with the Chinese SFDA, FDA and drug-induced liver injury experts to discuss developing a collaborative Chinese DILI network
155. 10/30/12 – Research Triangle Institute International
RTP, NC
Invited speaker: Why good drugs are sometimes bad for the liver
156. 10/9/12 – Liver Safety Assessment in Clinical Drug Development: Best Practices
Workshop
Boston, MA
Organizer of workshop
- 157.

GRANT SUPPORT

Past:

A.D. Williams Award (7,500) 1/86

Veterans Administration Career Development Awards

Associate Investigator 7/84-7/86 (70,000)

Research Associate 1/87-1/91 (350,000 total, 260,000 direct))

NIH, RO1 Award GM38149-01,

Title: "The environmental and genetic factors regulating HLP"

P.I. Paul B. Watkins

Project Period: 8/86-8/89

Total Direct costs: 300,000 total, 210,000 direct

NIH, RO1 Award GM 38149 -12

Title: "CYP 3A4 and CYP3A5 in human intestine"

P.I.: Paul B. Watkins

Project Period: 8/1/94-7/31/98

Annual Direct costs: \$191,000

Total Direct Costs: \$802,000

NIH, R22 ESU5770-01

Title: "Noninvasive assays of P450III A enzymes in man"

P.I.: Paul B. Watkins

Project Period: 9/1/91 - 9/1/93

Total Direct Costs: \$100,000 total;\$80,000 direct

Annual Direct Costs: 40,000

NIH, R32 DK09280-02

Title: Human intestinal flavin monooxygenases

P.I. Paul B. Watkins, mentor for Vas Janardan

Project period 07/15/95 - 07/14/97

Total Direct Costs: 33,000 (salary support for Dr. Janardan).

NIH, PO1 ES04238

Title: "Integrated Clinical and Basic Studies in Toxicology"

Project Director: Philip Guzelian, M.D.

Annual Direct Costs: \$650,000

Total Direct Costs: \$3,000,000

Total Project Period: 3/1/92 - 2/28/97

Subproject:

P.I.: Paul Watkins, M.D.

Title: Noninvasive Assays of P450III A Enzymes in Man

Total Project Period: 3/1/92 - 3/1/97

Total Direct Costs: \$625,034

Annual Direct Costs: \$120,000

NIH SBIR R43 - GM50067

Title: "13C-erythromycin breath test to determine drug dosages"

Project Director: David Wagner, Ph.D.

Total Direct Costs: \$513,132

Total project period: 7/1/96 - 1/1/99

Fujisawa Healthcare System

Title: "Predicting tacrolimus bioavailability from hepatic and enteric
P-450 catalytic activity"

Project Director: Paul B. Watkins

Total direct costs: \$96,000

Total project period: 7/1/98 - 7/1/99

NIH, NRSA Award F32 GM19034-01

Title: "Intestinal p-gp: Midazolam vs cyclosporine disposition"

Fellow: Mary Paine, Ph.D.

Mentor: Paul B. Watkins

Total Direct Costs: \$79,312

Total project period: 8/1/97 - 7/31/2000

Effort: 0%

NIH-5-M01-RR00042-31

Title: General Clinical Research Center

P.I.: Eugene Orringer, M.D.

Project Period: 12/01/99 - 11/30/10

Total Direct Costs: \$41M

Effort: 40% (Salary Only)

NIH – 1U54RR024383-01

Title: UNC Clinical and Translational Award

PI: Paul B. Watkins

Project period: 6/1/08 – 5/31/13

Total Direct Costs: \$62M

Effort: 50%

NIH, R-37 Merit Award GM 38149 -22

Title: "Effect of furanocoumarins and drugs on CYP3A4"

P.I.: Paul B. Watkins

Project Period: 9/1/99-8/31/10 (no cost extension)

Total Direct Costs: \$3,676,000

Effort: 30%

Gates Foundation

Title: Mechanisms underlying liver and kidney toxicity of DB289

PI: Richard Tidwell

Project period 12/1/09 – 11/30/11

Direct Costs: \$1.5 M

Effort: 10%

Current grant support:

Doris Duke Charitable Foundation
Title: Fellowship in Clinical Research for Medical Students
PI: Paul B. Watkins
Project Period: 7/1/05 – 6/30/12
Total direct costs: \$800,000
Effort: 5%

NIH -UO1 DK065201
Title: Drug Induced Liver Injury Network
PI: Paul B. Watkins
Project period: 9/1/03 – 8/31/13
Total direct cost: \$1,250,000
Effort: 20%

NIH,1RC1DK087510-01
Title: Revolutionizing preclinical safety testing
PI: Watkins and Threadgill, (Dual PIs)
Project period: 9/1/09 – 7/30/12
Direct costs: \$1M
Effort: 10%

NIH/NIGMS, 1T32GM086330-01
Title: UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
PI: Benjamin, Brouwer and Watkins (Multiple PIs)
Project Period: 7/1/11 – 7/31/16

CERTIFICATION AND LICENSURE

Medical Licensure: Michigan #050421
North Carolina #99-0163

Board Certification: Internal Medicine, 1982
Gastroenterology, 1984

HONORS AND AWARDS

Alpha Omega Alpha, 1978

Veterans Administration Career Development Awards
Associate Investigator, 7/84-7/86
Research Associate, 1/87-1/91

Who's Who of Young Americans, 1990

"One of 10 Best Lecturers", Introductory Clinical Sciences Courses, University of
Michigan Medical School, 1989

American Society for Clinical Investigation, 1993

Fellow, American College of Physicians, 1994

1995 Best Paper Award - Drug Metabolism and Disposition

Dean's Award to "Highly Meritorious Faculty", 1994

Pfizer Visiting Professor in Clinical Pharmacology to Tufts/New England Medical Center, 1996

Therapeutic Frontiers Lecture Award, American College of Clinical Pharmacy, 1998

NIH, MERIT Award, 1998-2008

Food and Drug Administration Visiting Professor – 2000.

Graduate Student Research Prize (1st place, Shefali Malhotra), ISSX meeting in Munich, Germany – 2001

The Burton Shatz Visiting Professor
Washington University, St Louis 6/30/04

Honorary Membership - Society of Toxicologic Pathology – Presented after Key Note Lecture at 2004 Annual Meeting in Salt Lake City

The Hyman Zimmerman State-of-the-Art Lecture
Annual meeting of the American Association for the Study of Liver Diseases, 11/1/04

Annual National Clinical Research Meetings
Presented “State of the Art” Plenary Lecture, 4/28/05

“Highly Cited Researcher” - Among most cited authors in pharmacology worldwide 1983-2002. ISIHighlyCited.com

Association of American Physicians, 2006

Goldberg Lecture: University of Chicago 2008

Fellow, American Gastroenterology Association 2009

Sterling Lecture: Tufts University Medical School 2009

O'Doul Visiting Professorship – University of Kansas 2009

Outstanding Published Paper “Advancing the Sciences of Risk Assessment” – Society of Toxicology, 2009

State-of-the-Art-Lecture at Digestive Disease Week, the annual meeting of the American Gastroenterology Association, Chicago, 2011

MEMBERSHIPS

American Association for the Study of Liver Diseases (AASLD)
American Association for the Advancement of Science (AAAS)
American College of Physicians (ACP)
American Federation for Medical Research (AFMR)
American Gastroenterological Association (AGA)
American Society for Clinical Investigation (ASCI)
American Society for Clinical Pharmacology and Therapeutics (ASCPT)
American Society for Pharmacology and Experimental Therapeutics (ASPET)
Association of American Physicians (AAP)
International Association for the Study of the Liver (IASL)
International Society for the Study of Xenobiotics (ISSX)
North Carolina Medical Society (NCMS)
Society of Toxicology (SOT)

TEACHING ACTIVITIES

Invited talks:

The University of Michigan Medical Center
Medicine Grand Rounds
1/27/87
Topic: Drug Reactions and Interactions

Medical College of Virginia, Department of Medicine
Medical Grand Rounds
3/3/88
Topic: Understanding Idiosyncratic Drug Reactions

Maine Medical Center, Department of Psychiatry
Grand Rounds
11/15/88
Topic: Drug Interactions: What a psychiatrist should know

Medical College of Wisconsin
Research Seminar - Departments of Pharmacology and Biochemistry
3/7/89
Topic: P-450III cytochromes: From rats to patients

The University of Michigan Medical Center, Department of Medicine
Grand Rounds
4/21/89
Topic: Drugs and the Liver, An Update

The University of Alabama
Gastroenterology Seminar

9/21/89
Topic: Drugs and the Liver

Vanderbilt University, Nashville, Tennessee
Pharmacology Seminar
9/10/90
Topic: Noninvasive Assays of P450III A in Patients

Delaware Valley Drug Metabolism Group, Philadelphia, PA
5/30/91
Topic: Clinical uses of noninvasive assays of P450III A

University of Michigan
Medical Grand Rounds
3/23/92
Topic: Why are good drugs bad for some people?

Medical College of Virginia
Medical Grand Rounds
4/16/92
Topic: Why are good drugs bad for some people?

University of Pittsburgh
Visiting Professor
Division of Clinical Pharmacology
5/6-5/7/92
Topic: Clinical relevance of interpatient differences in P450III A activity

Indiana University
Visiting Professor
Department of Medicine Grand Rounds
12/8 - 12/9/92
Topic: Clinical Applications of Molecular Pharmacology

University of Colorado
Visiting Professor
Division of Clinical Toxicology
4/8 - 4/9/93
Topic: The Erythromycin Breath Test

Wayne State University
Visiting Professor
Institute of Chemical Toxicology
7/10/93
Topic: The intestine as a metabolic barrier

University of Cincinnati
Visiting Professor
Department of Environmental Toxicology
11/2 - 11/3/93
Topic: Clinical Significance of Intestinal CYP3A

University of Chicago

Visiting Professor
Department of Pharmacology
6/23/94
Topic: The clinical relevance of CYP3A enzymes

University of California San Francisco
Visiting Professor
Department of Pharmacy
1/6/95
Topic: The intestinal barrier.

University of Upsala, Sweden
Visiting Professor
Department of Clinical Pharmacology
5/16 -5/17/95

Michigan Society of Toxicology
Invited Plenary Talk
5/19/95
Topic: CYP3A4: Studies in rats and patients

Indiana University Medical Center
Visiting Professor
Department of Medicine
10/19/96

Tufts Medical School
Pfizer Visiting Professor in Clinical Pharmacology
11/19 - 11/21/96
Boston Mass.

University of Florida
Visiting Professor
Department of Medicine
Gastroenterology Research Seminar
2/16-2/17/98
Topic: The grapefruit juice effect

Georgetown University
Visiting Professor
Department of Medicine Grand Rounds
9/2- 9/3/98
Topic: Why good drugs are bad for some people

Research Triangle Park Drug Metabolism Discussion Group
Inaugural Banquet Guest Speaker
10/14/99

Topic: Citrus juices and intestinal barrier function in man: Not pulp fiction

National Institutes of Environmental Health Sciences
Toxicology Seminar Series
11/6/03

Topic: Food: drug interactions – Lessons for Grapefruit Juice

Harvard University – Brigham and Women's Hospital
Visiting Professor and presenter at GI Grand Rounds
1/29/03

Topic: Understanding Idiosyncratic Drug Induced Liver Disease

Washington University, St Louis
The Burton Shatz Visiting Professor
Medical Grand Rounds
6/30 – 6/31/04

Topic: Understanding Drug Induced Liver Disease

University of Kentucky
Gastroenterology Symposium
Invited Speaker
12/3/04

Topic: Drug Induced Liver Disease

University of Connecticut Medical School
Visiting Professor
Medical Grand Rounds
1/15-16/05

Topic: Why are good drugs sometimes bad for the liver?

University of Florida Medical School
Visiting Professor
Medical Grand Rounds
1/19/ - 1/20/05

Topic: Why are good drugs sometimes bad for the liver?

Indiana University Medical School
Visiting Professor
Medical Grand Rounds
3/8 – 3/9/05

Topic: Why are good drugs sometimes bad for the liver?

Duke University Medical School
Visiting Professor
Medical Grand Rounds
3/25/05

Topic: Why are good drugs sometimes bad for the liver?

Moi Referral Hospital, Eldoret Kenya
Visiting Professor
7/12/05 – 8/7/05

University of Texas South Western
GI Grand Rounds
5/11/06- 5/12/06
Topic: Drug Induced Liver Disease

University of Chicago

The Goldberg Lecture
11/26/09
Topic: New approaches to understand drug-induced liver injury

NC State University
9/15/09
Toxicology Seminar Series
Topic: New approaches toward biomarkers for drug safety

University of North Carolina
Department of Medicine Grand Rounds
12/3/09
Topic: Why good drugs are sometimes bad for the liver.

University of North Carolina
Institute for Pharmacogenomics and Individualized Therapy
1/12/10
Topic: Understanding hepatotoxicity: from man to mouse to computer

University of North Carolina
Advanced Toxicology
2/26/10
Topic: Human Toxicology: Drug-induced Liver Injury Part 1

University of North Carolina
Advanced Toxicology
3/1/10
Topic: Human Toxicology: Drug-induced Liver Injury Part 2

University of North Carolina
GPEN 2010 (Globalization of Pharmaceutical Education Network)
11/11/10
Topic: Drug-Induced Toxicity: A Major Factor in the Clinical Failure of Drug Candidates

Duke University
Duke University Integrated Toxicology and Environmental Health Program
1/28/11
Topic: Idiosyncratic Hepatotoxicity

University of North Carolina
Advanced Toxicology
2/21/11
Topic: Human Toxicology: Drug-induced Liver Injury Part 1

University of North Carolina
Advanced Toxicology
2/23/11
Topic: Human Toxicology: Drug-induced Liver Injury Part 2

Duke Clinical Research Institute
Duke Clinical Research Institute's Research Conference

5/31/11
Topic: When good drugs are bad for the Liver

Duke University
Duke Integrated Toxicology and Environmental Health Program
9/9/11
Topic: Idiosyncratic Hepatotoxicity

University of North Carolina at Chapel Hill
Drug Metabolism Course MOPH810 Fall 2011
10/25/11
Topic: Drug and Metabolite-Induced Hepatotoxicity

University of North Carolina at Chapel Hill
Clinical Pharmacology Forum
12/2/11
Topic: Drug Metabolism and DDI

University of North Carolina at Chapel Hill
Advanced Toxicology
2/29/12
Topic: Human Toxicology: Drug-induced Liver Injury Part 1

University of North Carolina at Chapel Hill
Advanced Toxicology
3/2/12
Topic: Human Toxicology: Drug-induced Liver Injury Part 2

University of Southern California
Keck School of Medicine Seminar
10/11/12
Topic: Understanding Drug Induced Liver Injury: From man to mouse to computer

University of North Carolina at Chapel Hill
Drug Metabolism – Dr. Dhiren Thakker
11/1/12
Topic: Drug Metabolism Induced Liver Toxicity

University of North Carolina at Chapel Hill
Theory and Practice of evaluating human health risks of chemical (ENVR 742)
– Dr. Ivan Rusyn
11/5/12
Topic: Drug Development in 2012

AASLD: The Liver Meeting 2012
AASLD Postgraduate course
Invited speaker
Topic: Causes and Clinical Features of Drug-induced Liver Injury (DILI): State-of-the-Art
Boston, MA
11/9/12

AASLD: The Liver Meeting 2012
AASLD Meet the Professor Luncheon
Role: Co-moderator
Title: Pharmacogenetics and Drug-induced Liver Injury
Boston, MA
11/10/12

University of North Carolina at Chapel Hill
Pulmonary and Gastrointestinal Therapeutics Fall 2012 (PHCY 445)
11/15/12
Topic: Liver Anatomy, LFTs and Drug Induced Liver Disease

Doctoral Thesis Committees

- | | |
|----------------------|--------------|
| 1). Zinge Hsu | 1994 |
| 2). Ching Ling | 1996 |
| 3). Yuan Zing | 1998 |
| 4). Keith Hoffmaster | 2001 |
| 4). Matthew Troutman | 2002 |
| 5). Allison Hege | 2006-2008 |
| 6). Tracy Marion | 2008-2010 |
| 7). Latoya Griffin | 2009-2012 |
| 8). Kyunghee Yang | 2011-present |

Mentor for Medical Students in Doris Duke Clinical Research Fellowship

- | | |
|--------------------|-----------|
| 1). Ray Givens | 2001-2003 |
| 2). Sheela Agarwal | 2004-2005 |
| 3). Sara Peterson | 2006-2007 |

Mentor for Senior House Office Projects

- | | |
|---------------------|-----------|
| 1) Laurie Winkleman | 1987-1988 |
| 2) Kenneth Lown | 1988-1989 |
| 3) Kevin Foley | 1988-1989 |
| 4). Howard Ro | 1996-1997 |
- (Winner of 1997 Research Prize)

Mentor for UNC Program in Translational Medicine

- 1). Natalie Holman

Gastroenterology Fellows/Postdoctoral Students

- | | |
|-------------------|-----------|
| 1) Joseph Kolars | 1987-1990 |
| 2) Kim Turgeon | 1989-1991 |
| 3) Ken Lown | 1990-1993 |
| 4) Vas Janardan | 1993-1996 |
| 5) Robert Fontana | 1993-1995 |

6) Mary Paine	1997-1999
7) Claire Dees (K23)	2000-2007
8). Mark Russo (K-12/K-23)	2003-2007
9). Alison Harrill	2009-2010
10). Kristina DeSmet	2009-2011
11). Daniel Gatti	2010-2011
12). Brett Howell	2010-2011
13). Catherine Lisa Kurtz	2010-2012
14). Jeff Woodhead	2011-present
15). Jingtao Lu	2012- present

Graduate Students

1) Fang Che	1991-1993
2) Laurie Fortlage	1993-1994
3). Maria Banach	1997-1999
4). Shefali Malhotra	1998-2002
5). Stephane Mouly	1999-2001
6). Kyunghee Yang	2012-present

INSTITUTIONAL ADMINISTRATIVE ACTIVITIES:

Chairman, Department of Medicine Finance Committee 1993

University of Michigan Toxicology Training Grant Committee 1995 - 99

Deans' Search Committee for The Chairman of Department of Epidemiology 1995 - 96

Chairman, Dean's Task force for Clinical Research 10/96 - 5/97

Internal Review Committee for The Department of Medicine 6/98 -10/98

Dean's Advisory Council on Clinical Research 2/98 - 8/99

Howard Hughes New Initiatives committee 10/98 – 8/1/99

Search Committee for Associate Dean of Research 11/98 – 6/99

Advisory Committee for Center for Clinical Investigation and Therapeutics 12/98 – 8/99

Dean's Scientific Advisory Committee 8/99 – present

Clinical Research Advisory Committee 8/99 – present

Chair, Clinical Research Advisory Committee for Industry Research 1/00 – 7/02

Chairman, Investigational Drug Service Advisory Committee 6/00 - present

Advisory Board for Building Interdisciplinary Research Careers in Women's Health (BIRCWH – K-12) Program 8/99 - present

Medical Student Research Advisory Committee 7/01 – present
School of Medicine HIPAA Compliance Steering Committee – 12/02 – present
Chair, Dean's Committee for Five Year Review of Cystic Fibrosis Center Director
(Richard Boucher, M.D.) 1/03 – 5/03
Director, Mentored Clinical Research Scholars Program (K-12), 7-02-present
Division of Pharmacotherapy Search Committee – 1/01/04 – 8/1/04
Department of Psychiatry Chairman Search Committee 9-01-04 – 6-01-05
Dean's Translational Research Committee 2/05 – present
Advisory Committee – Center for Function Bowel Disease 6/04 – present
UNC Research Compliance Task Force 11/05 – present
Principal Investigator– Clinical Translational Science Award application 7/06 -7/08
Member of TraCS Steering Committee for the CTSA renewal 2012- present

BIBLIOGRAPHY

Completed publications in scientific journals

Peer-reviewed journals

1. Rapoport, S., Watkins, P.B.: Descending motor paralysis caused by c. botulinum isolated from a clinically occult wound. *Annals of Neurology* 1984; 16:359.
2. Wrighton, S.A., Schuetz, E.G., Watkins, P.B., Whitley, B., Guzelian, P.S.: Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. *Biochemistry* 1985; 24: 2171.
3. Wrighton, S.A., Schuetz, E.G., Watkins, P.B., Barwick, J., Bailey, B.S., Hartle, H.T., Young, B., Guzelian, P.S.: Demonstration in multiple species of glucocorticoid inducible hepatic cytochromes P-450 in the rat. *Molecular Pharmacology* 1985; 28:312.
4. Watkins, P.B., Wrighton, P.S., Maurel, P., Mendez-Picon, G., Parker, G.S., Guzelian, P.S.: Identification of an inducible form of cytochrome P-450 in human liver. *Proc Natl Acad Sci* 1985; 82:6310.
5. Schuetz, E.G., Hazelton, G.A., Hall, J., Watkins, P.B., Klaassen, C.D., Guzelian, P.S.: Induction of digitoxigenin monodigitoxoside UDP-Glucuronosyltransferase activity by glucocorticoids and other inducers of cytochrome P-450p in primary monolayer cultures of adult rat hepatocytes and in human liver. *J Biol Chem* 1986; 261:8270.

6. Watkins, P.B., Wrighton, S.A., Schuetz, E.G., Maurel, P., Guzelian, P.S.: Macrolide antibiotics inhibit the degradation of the glucocorticoid-responsive cytochrome P-450p in rat hepatocytes in vivo and in primary monolayer culture. *J Biol Chem* 1986; 261:6264.
7. Wrighton, S.A., Campanile, C., Thomas, P.E., Maines, S.L., Watkins, P.B., Parker, G., Mendez-Picon, G., Haniu, M., Shively, J.E., Levin, W., Guzelian, P.S.: Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. *Molecular Pharmacology* 1986; 29:405.
8. Molowa, D.T., Schuetz, E.G., Wrighton, S.A., Watkins, P.B., Kremers, P., Mendez-Picon, G., Parker, G.A., Guzelian, P.S.: Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. *Proc Natl Acad Sci* 1986; 83:5311.
9. Wrighton, S.A., Thomas, P.E., Molowa, D.T., Haniu, M., Shively, J.E. Maines, S.L., Watkins, P.B., Parker, G., Mendez-Picon, G., Levin, W., Guzelian, P.S.: Characterization of ethanol-inducible human liver N-nitrosodimethylamine demethylase. *Biochemistry* 1986; 25:6731.
10. Wrighton, S.A., Thomas, P.E., Willis, P., Maines, S.L., Watkins, P.B., Levin, W., Guzelian, P.S.: Purification of a human liver cytochrome P-450 immunochemically-related to several cytochromes P-450 purified from untreated rats. *J Clin Invest* 1987; 80:1017.
11. Watkins, P.B., Wrighton, S.A., Schuetz, E., Molowa, D., Guzelian, P.S.: Identification of dexamethasone inducible cytochromes P-450 in intestinal mucosa of rat and man. *J Clin Invest* 1987; 80:1029.
12. Watkins, P.B., Carithers, R., Mills, S., VanThiel, D.: Fatal hepatitis associated with parenteral gold therapy: A report of two cases. *Digestive Diseases* 1988; 33(8):1025-1029.
13. Watkins, P.B., Murray, S.A., Winkleman, L., Heuman, D., Wrighton, S.A., Guzelian, P.S.: The erythromycin breath test as an assay of hepatic glucocorticoid-inducible cytochromes P-450: Studies in rats and patients. *J Clin Invest* 1989; 83:688-697.
14. Wrighton, S.A., Ring, B.J., Watkins, P.B., Vauden Branden, M.: Identification of a polymorphically expressed member of the human cytochrome P-450III family. *Molec Pharmacol* 1989; 36:97-105.
15. Watkins, P.B., Murray S.A., Thomas, P.E., Wrighton, S.A.: Distribution of cytochromes P-450, cytochrome b₅, and NADPH-cytochrome P-450 reductase in an entire human liver. *Biochem Pharmacol* 1990; 39:471-476.
16. Lucey, M.R., Kolars, J.C., Merion, R.H., Campbell, D.C., Aldrich, M., Watkins, P.B.: Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450IIIA. *Lancet* 1990; 335:11-15.

17. Watkins, P.B., Hamilton, T., Ellis, C., Kolars, J., Voorhees, J.: The erythromycin breath test as a predictor of cyclosporine A blood levels. *Clin. Pharmacol. Ther.* 1990; 48:120-129.
18. Murphy, R., Swartz, R., Watkins, P.B.: Severe toxicity due to acetaminophen in a patient receiving isoniazid. *Annals of Internal Medicine* 1990; 113:799-800.
19. Watkins, P., The cytochromes P-450. *Gastroenterology International* 1990; 3(4):184-188.
20. Kolars, J., Murray, S.A., Peters, K.M., Watkins, P.B.: Differential regulation of P-450III genes in choline deficient rats. *Hepatology* 1990; 12:1371-1378.
21. Watkins, P.B.: P-450 enzymes and cyclosporine metabolism. *American Academy of Dermatology* 1990; 23(6):1301-1311.
22. Grier, R.E., Heard, G.S., Watkins, P., Wolf, B.: Low biotinidase activities in the serum of patients with impaired liver function: Evidence that the liver is the source of serum biotinidase. *Clin. Chim. Acta* 1990; 186(3):397-400.
23. Wrighton, S.A., Watkins, P.B.: Non uniform distribution of cytochrome P450IA2 in liver. *Gastroenterology* 1991; 100(5) 1487-1488 (Letter).
24. Kolars, J.C., Awni, W.M., Merion, R.M., Watkins, P.B.: "First-pass" metabolism of cyclosporin A by the gut. *Lancet* 338:1488-1491, 1991.
25. Turgeon, D.K., Kolars, J., Watkins, P.B. Omeprazole and aryl hydrocarbon hydroxylases - should we be worried? *Hepatology* 1991; 13(1):197-198.
26. Watkins, P.B. Anti-microsomal autoantibodies - are they telling us something? *Hepatology* 1991; 13(2):385-386.
27. Lown, K. and Watkins, P.B. Predicting drug interactions in cultured human hepatocytes. *Hepatology* 1991; 14(2):396-398.
28. Lown, K.S., Kolars, J.C., Turgeon, K., Merion, R., Wrighton, S.A., Watkins, P.B.: The erythromycin breath test selectively measures P450IIIA in patients with severe liver disease. *Clin. Pharmacol. Ther.* 51(3):229-238, 1992.
29. Kolars, J.C., Schmiedlin-Ren, P., Dobbins III, W.O., Schuetz, J., Wrighton, S.A., Watkins, P.B.: Heterogeneity of Cytochrome P450IIIA Expression in Rat Gut Epithelia. *Gastroenterology* 102:1186-1198, 1992.
30. Hunt, C.M., Watkins, P.B., Saenger, P., Stave, G.M., Barlascini, N., Watlington, C.O., Wright, Jr., J.T., Guzelian, P.S.: Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. *Clin. Pharmacol. Ther.* 51(1):18-23, 1992.
31. Kolars, J.C., Stetson, P.J.L., Rush, B.D., Ruwart, M.J., Schmiedlin-Ren, P., Duell, E.A., Voorhees, J.J., Watkins, P.B.: Cyclosporin metabolism by P450IIIA in rat enterocytes - another determinant of oral bioavailability? *Transplantation* 1992; 53:596-602.

32. Watkins, P.B., Turgeon, D.K., Kolars, J.C., Lown, K.S., Fishman, K., Saenger, P., Hamilton, T., Guzelian, P., Voorhees, J.: Comparison of urinary 6- β -cortisol and the erythromycin breath test as measures of hepatic P450III_A activity. *Clin. Pharmacol. Ther.* 1992; 52:265-73.
33. Kolars, J.C., Schmiedlin-Ren, P., Schuetz, J.D., Fang, C., Watkins, P.B.: Identification of rifampin-inducible P450III_A4 (CYP3A4) in human small bowel enterocytes. *J. Clin. Invest.* 1992; 90:1871-1878.
34. Turgeon, D.K., Normolle, D.P., Leichtman, A.B., Annesley, T.M., Smith, D.E., Watkins, P.B.: Erythromycin breath test predicts oral clearance of cyclosporine A in renal transplant recipients. *Clin. Pharmacol. Ther.* 1992; 52:471-480.
35. Watkins, P.B., Turgeon, D.K., Guthrie, S.K., Remen, A., Grunhaus, L.J.: P450III_A (CYP3A) activity in severe depression. *Journal of Clinical Psychopharmacology.* 1993; 13:366-368.
36. Watkins, P.B. Omeprazole and induction of P450I_A2: The importance of studying the appropriate human model. *Hepatology* 1993;17(4):748.
37. Schmiedlin-Ren, P., Benedict, P.E., Dobbins III, W.O., Ghosh, M., Kolars, J.C., Watkins, P.B.: Cultured adult rat jejunal explants as a model for studying regulation of P450III_A (CYP3A). *Biochem. Pharmacol.* 1993; 46:905-918.
38. Kolars, J.C., Benedict, P., Schmiedlin-Ren, P., Watkins, P.B.: Aflatoxin B1 adduct formation in small bowel enterocytes of rat and man. *Gastroenterology*, 1994; 106:433-43.
39. Watkins P.B. Tacrine and Transaminases. *Alzheimer Disease and Associated Disorders* 8 (S2) S-32 - S38, 1994.
40. Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., Lewis, K.W.: Hepatotoxic effects of tacrine administration in patients with Alzheimer's Disease. *J.A.M.A.*, 1994; 271:992-998
41. Turgeon, DK, Leichtman, AB, Blake, DS, Schmouder, RL, Lown, KS, Annesley, TM, Watkins, PB. The erythromycin breath test predicts inter and intra patient variation in OG 37-325 dosing requirements: A prospective study in renal transplant recipients. *Transplantation*, 1994;57:1736-1741.
42. Watkins, P.B. Noninvasive tests of CYP3A enzymes. *Pharmacogenetics* 1994; 4:171-184.
43. Turgeon, DK, Leichtman, AB, Lown, KS, Normolle, DP, Deeb, GM, Merion, RM, Watkins, PB: P450III_A(CYP3A) activity and cyclosporin A dosing in renal and cardiac transplant recipients. *Clin. Pharmacol. Ther.*, 1994; 56:253-60.
44. Kolars, J.C., Lown, K.S., Schmiedlin-Ren, P., Fang, C., Wrighton, S.A., Merion, R., Watkins, P.B. CYP3A Gene Expression in Human Gut Epithelium. *Pharmacogenetics.*, 1994; 4:247-259.
45. Lown, K.S., Kolars, J.C., Thummel, K.E., Barnett, J., Kunze, K., Wrighton, S.A., Watkins, P.B. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5

- in small bowel; Lack of prediction by the Erythromycin Breath Test. *Drug Metab. Dispo.*, 1994; 22:4:947-955.
46. Lown, K.S., Thummel, K.E., Benedict, P., Turgeon K., Kolars, J.C., Watkins, P.B. The erythromycin breath test predicts intravenous kinetics of midazolam. *Clin. Pharmacol. Ther.* 1995;57:16-24.
 47. Watkins, P.B. Midazolam, cyclosporine, and P450 3A in liver transplant recipients. *Hepatology*, 22:3;998-1001,1995
 48. Jaffe, C.A., Turgeon, D.K., Friberg, R.D., Watkins, P.B., Barkan, A.L.: Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin-a clinical research center study. *J. Clin Endo Metab* 1995;80:3321-3326.
 49. Inaba, T, Nebert, D.W., Burchell, B., Watkins, P.B., Goldstein, J.A., Bertilsson, L., and Tucker, G.T. Pharmacogenetics in clinical pharmacology and toxicology *Canadian J. Physiol. Pharmacol*, 1995; 73:331-338.
 50. Lampen, A., Christians, U., Guengerich, F.P., Watkins, P.B., Kolars, J.C., Bader, A., Dralle, H., Hackbarth, I., and Sewing K.-F., Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions and interindividual variability. *Drug Metab. Dispo.*, 1995; 23:1315-1324.
 51. Jaffe CA. Turgeon DK. Friberg RD. Watkins PB. Barkan AL. Nocturnal augmentation of growth hormone (GH) secretion is preserved during repetitive bolus administration of GH-releasing hormone: potential involvement of endogenous somatostatin--a clinical research center study. *Journal of Clinical Endocrinology & Metabolism*. 80(11):3321-6, 1995 Nov.
 52. Fontana, R.J., Turgeon, D.K., Woolf, T.F., Knapp, M.J., Foster, N., Watkins, P.B., Tacrine hepatotoxicity: The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. *Hepatology* 1996; 231:1429-1435.
 53. Janardan, S.K., Lown, K.S., P. Schmiedlin-Ren, P., Watkins, P.B. Selective expression of CYP3A5 and not CYP3A4 in human blood. *Pharmacogenetics* 6:379-385,1996.
 54. Haehner, B, Wrighton, S.A., Janardan, S.K., Watkins, P.B., Hall, S.A. Expression of CYP3A enzymes in human kidney. *Molecular Pharmacology* 50:52-59,1996.
 55. Watkins, P.B.: Erythromycin Breath Test and Clinical Transplantation. *Therapeutic Drug Monitoring* 1996; 18:368-371.
 56. Lown, K.S., Bailey, D.G., Fontana, R, Janardan, S.K., Adair, C.H., Fortlage, L., Brown, M.B., Guo, W., Watkins, P.B. Grapefruit juice increases felodipine oral availability in man by decreasing intestinal CYP3A protein expression. *J. Clin. Invest.* 1997: 99:2545-2553.
 57. Jamis-Dow, C.A., Pearl, M.L., Watkins, P.B., Blake, D.S., Klecker, R.W., Collins, J.M. Predicting drug interactions in vivo from experiments in vitro: human

- studies with paclitaxel and ketoconazole. *Amer. J. Clin. Oncology* 1997; 20(6): 592-599.
58. Schmiedlin-Ren, P, Thummel, K.E., Fisher, Jeanine, M., Paine, M.F. Lown, K.S., Watkins, P.B. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1 α ,25-dihydroxyvitamin D₃. *Molecular Pharmacology* 1997; 51:741-754.
 59. Cheng, C.L., Smith, D.E., Carver, P.L., Cox, S.R., Watkins, P.B., Blake, D.S., Kauffman, C.A., Meyer, K.M, Amidon, G.L., Stetson, P.L. Steady State pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. *Clin. Pharmacol. Ther.* 1997; 61:531-543.
 60. Lown, K.S., Mayo, R, Leichtman, A.B., Hsiao, H.L., Turgeon, D.K., Blake, D.S., Schmiedlin-Ren, P., Brown, M.B., Wensheng, G. Benet, L.Z., Watkins, P.B. The role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin A. *Clin. Pharmacol. Ther.* 1997; 62:248-60.
 61. Schmiedlin-Ren, P., Edwards, D.J., Fitzsimmons, M.E., He, K., Lown, K.S., Woster, P.M., Rahman, A., Thummel, K.E., Fisher, J.M., Hollenberg, P.F., Watkins, P.B.: Mechanisms of Enhanced Oral Availability of CYP3A4 Substrates by Grapefruit Constituents: Decreased Enterocyte CYP3A4 Concentration and Mechanism-Based Inactivation by Furanocoumarins. *Drug Metab. Dispo.* 1997; 25:1228-1233.
 62. Lown, K.S., Ghosh, M. Watkins, P.B. Hepatic and intestinal CYP3A4 cDNAs are identical. *Drug Metab. Dispo.* 1998; 26(2):185-7
 63. Watkins, P.B., Whitcomb, R. Hepatic Dysfunction Associated with Troglitazone. *New England Journal of Medicine (letter to editor)* 1998; 338(13): 916-7.
 64. Fontana, R.J., deVries, T.M., Woolf, T.F., Knapp, M.J., Kaminsky, L.S., Tang, B., K., Foster, N., Watkins, P.B., Caffeine based measures of CYP1A2 activity predict oral clearance of tacrine. *Br. J. Clin. Pharmacol.* 1998; 46:221-228.
 65. Edwards D., Fitzsimmons, M.E., Schuetz, E.G., Yasuda, K., Ducharme, M.P., Warbasse, L.H., Woster, P.M., Schuetz, J.D., Watkins, P.B.: 6,7 dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4 and P-glycoprotein. *Clin. Pharmacol. Ther.* 1999; 65(3):237-244.
 66. Hall, S.D., Thummel, K.E., Watkins, P.B., Lown, K.S., Benet, L.Z., Paine, M.F., Mayo, R.R., Turgeon, K., Bailey, D.G., Fontana, R.J., Wrighton, S.A. Molecular and physical mechanisms of first-pass extraction. *Drug Metab. Dispo.* 1999; 27(2): 161-166.
 67. Paine, MJ, Schmeidlin-Ren, P. Watkins, P.B., CYP1A1 expression in human small bowel; Interindividual variation and inhibition by ketoconazole. *Drug Metab. Dispo.* 1999; 27(3):360-364.
 68. Fisher, J.M., Wrighton, S.A., Watkins, P.B., Schmeidlin-Ren, P., Calamia, J.C., Shen, D.D., Kunze, K.L., Thummel, K., E. First-pass midazolam metabolism

- catalyzed by 1 α ,25-dihydroxy vitamin D₃ modified Caco-2 cell monolayers. *J. Pharmacol. Ther.* 289(2):1134-1142,1999.
69. Fontana, R.J., Lown, K.S., Paine, M.F., Fortlage, L., Santella, R.M., Felton, J. S., Knize, M.G., Greenberg, A., Watkins, P.B. Effects of chargrilled meat on the expression of CYP3A, CYP1A and p-glycoprotein levels in healthy volunteers *Gastroenterology* 117:89-98,1999.
 70. Leichtman, A., Watkins, P.B. The molecular basis of cyclosporin A metabolism, pharmacokinetics, and drug interactions, *Graft::Organ and Cell transplantation*, 2(5):177-182,1999.
 71. Hughes, S.J., Morse, M.A., Weghorst, C.M., Kim, H., Watkins, P.B., Guengerich, F.P., Orringer, M.B., Beer, D.G. Cytochromes P450 are expressed in proliferating cells in Barrett's Metaplasia. *Neoplasia* 1:145-153,1999.
 72. Thummel, K.E., Slattery, J.T., Ro, H., Chien, J.Y., Nelson, S.D., Lown, K.S., Watkins, P.B.: Ethanol Exposure and Acetaminophen Hepatotoxicity: Inhibition and Induction of Hepatotoxic Metabolite Formation. *Clin. Pharmacol. Ther.* 67:591-5999, 2000
 73. Hirth, J., Watkins, PB, Strawderman, M.S., Schott, A., Bruno, R., Baker, L. The effect of an individual's cytochrome CYP3A4 activity of docetaxel clearance. *Clin. Cancer Res.* 6:1255 – 1258, 2000.
 74. Watkins PB. COMT inhibitors and liver toxicity. *Neurology.* 55(11 Suppl 4):S51-2; discussion S53-6, 2000
 75. Watkins, P.B. The erythromycin breath test (letter) *Clin. Pharmacol. Ther.* 67:577, 2000.
 76. Wrighton, S.A., Schuetz, E.G., Thummel, K.E., Shen, D.D., Korzekwa, K.R., Watkins, P.B., The human CYP3A subfamily: Practical considerations. *Drug Metabolism Reviews* 32(3-4):339-361, 2000
 77. Malhotra S, Fitzsimmons ME, Bailey DG, Paine MF, Watkins PB. Seville Orange Juice Interaction with Felodipine: Comparison with dilute grapefruit juice and involvement of furocoumarins. *Clin. Pharmacol. Ther.* 69:14-23, 2001.
 78. Kuehl P, Zhang J, Lin Y, Watkins PB, Maurel P, Daly A, Wrighton S, Hall S, Relling M, Schuetz J, Brimer C, Yasuda K, Strom S, Thummel K, Schuetz E, Boguski M. The CYP3A Promoters: DNA Sequence Diversity and Concordance of One Allele with Polymorphic CYP3A5 Expression. *Nature Genetics* 2001; 27:383-389.
 79. Zhang J, Kuehl P, Green E, Touchman J, Watkins PB, Daly A, Hal SD, Maurel P, Relling M, Brimer C, Yasudo K, Hancock M, Kim R, Stom S, Thummel K, Russell C, Schuetz E, Buguski MS. The human Pregnane X Receptor: genomic structure and identification and functional characterization of natural allelic variants. *Pharmacogenetics* 2001; 11:555-72.

80. Schmiedlin-Ren, Thummel, K E, Fisher, JM, Pain MF, Watkins, PB. Induction of CYP3A4 by 1 α ,25-dihydroxyvitamin D₃ is human cell line specific and is unlikely to involve PXR. *Drug Metab Dispo* 29 (11):1446-53, 2001.
81. Lin, Y S, Lockwood, G, Brian, W, Loi, C, Dobrinska, MR, Shen, DD, Watkins, PB, Wilkinson, GR, Kharasch, ED, Thummel, KD. Single-Point Midazolam Concentration as a Phenotypic Marker for In Vivo CYP3A Activity. *Pharmacogenetics* 11:781-792, 2001.
82. Rivory, L.P., Watkins, PB. The Erythromycin Breath Test (Letter to Editor) *Clin. Pharmacol Ther* 70:395-69, 2001.
83. Zhang, J., Watkins, PB, Daly, A, Hal, SD, Maurel, P, Relling, M, Brimer, C, Yasudo, K, Hancock, M, Stom, S, Thummel, K, Russell, C, Schuetz, E, Boguski, MS. CYP3A4 genomic structure and identification and functional characterization of natural allelic variants. *Pharmacogenetics* 12(2):121-32, 2002.
84. Paine, MF, Leung, LY, Lim, HK, Liao, K, Oganessian, A, Zhang, M, Thummel, KE, Watkins, PB. Identification of a novel route of extraction of sirolimus in human small intestine: Roles of metabolism and secretion. *Journal of Pharmacology & Experimental Therapeutics*. 301(1):174-86, 2002.
85. Wanwimolruk, S., Paine, MF, Pusek, S, Watkins, PB. Is Quinine a suitable probe to assess the hepatic drug metabolizing enzyme CYP3A4? *Br. J. of Clin. Pharmacol* 54:643-51,2002.
86. Mouly S, Lown KS, Wille RT, Kornhauser D, Joseph JL, Fiske WD, Watkins PB. Hepatic but not intestinal CYP3A4 displays dose dependent induction by efavirenz in humans. *Clinical Pharmacology & Therapeutics*. 72(1):1-9, 2002.
87. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville GM, Guyer KE, Bates ER. Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction. *Circulation*: 10000047R-67R, 2002
88. Jaffe CA, Turgeon DK, Lown K. Demott-Friberg R, Watkins PB. Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. *Am J Physiol*. 283: E1008-E1015, 2002.
89. Paine MF, Wagner DA, Hoffmaster KA, Watkins PB. Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin. *Clin Pharmacol Ther* 2002;72:524-35
90. Kaplowitz N. Lewis JH. Watkins PB. Did this drug cause my patient’s hepatitis? (comment) *Annals of Internal Medicine* 2003;138;159-60.
91. Nelson SD, Slattery, JT, Thummel KE, Watkins PB. CAR unlikely to significantly modulate acetaminophen hepatotoxicity in most humans *Hepatology*, 38:254-257, 2003.

92. Givens RC, Lin YS, Dowling Am L.S., Thummel KE, Lamba JK, Schuetz EG, Stewart PW, and Watkins PB. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. *J. Appl. Physiol* 2003; 95: 1297 – 1300.
93. Givens RC, Watkins, PB, Pharmacogenetics and clinical gastroenterology. *Gastroenterology*. 125(1):240-8. 2003
94. Mouly SJ, Paine MF, Watkins, PB. Contributions of CYP3A4, p-glycoprotein and serum protein binding to the intestinal first-pass extraction of saquinavir. *J Pharmacol Exp Ther* 308:941-948, 2004
95. Huang SM, Hall SD, Watkins PB, Love LA, Serabjit-Singh C, Betz JM, Hoffman FA, Honig P, Coates PM, Bull J, Chen ST, Kearns GL, Murray MD. Drug interactions with herbal products and grapefruit juice: A conference report. *Clinical Pharmacology and Therapeutics* 2004; 75:1-12
96. Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville GM, Guyer KE, Tait AR Bates ER. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. *Circulation*: 109(2):166-71,2004.
97. Malhotra S, Paine MF, Watkins PB. 6'7'-dihydroxy bergamottin significantly contributes to the grapefruit juice effect. *Clin Pharmacol Ther* 75:569-79, 2004.
98. Paine MF, Leung LY, Watkins PB. New insights into drug absorption: studies with sirolimus. *Ther Drug Monit*, 26(5):463-7,2004
99. Russo MW, Galanko JA., Shrestha R, Fried MW, Watkins PB. Liver Transplantation for Drug Induced Liver Injury in the United States. *Liver Transplantation*. 10:1018-1023. 2004
100. Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? *Gastroenterology*. 126(5):1477-80,2004
101. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetics and binding properties. *Drug Metab Dispo* 32(10):1146-53,2004
102. Dees CE, Watkins PB. Role of cytochrome P450 phenotyping in cancer treatment. *J. Clin. Oncology* 23(8):1-3, 2005.
103. Paine MF, Criss AB, Watkins PB. Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition, *J Pharmacol Exp Ther*, 312(3):1151-60,2005
104. Paine MF, Ludington SS, Chen ML, Stewart PW, Huang SM, Watkins PB. Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? *Drug Metabolism and Disposition*, 33:426-33, 2005.
105. Watkins, PB. Insight into hepatotoxicity. The troglitazone experience. *Hepatology* 41(2):229-230, 2005.

106. Mouly SJ, Matheny C, Smith G, Lamba J, Lamba L, Paine MF, Pusek SM, Schuetz EG, Stewart P, Watkins PB. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of CYP3A5. *Clin Pharmacol Ther.* 78(6):605-18. 2005
107. Watkins, PB, Idiosyncratic Hepatocellular Injury: Challenges and Approaches. *Toxicological Pathology* 33(1), 1-5, 2005.
108. Kharasch ED, Thummel KE, Watkins PB. CYP3A Probes Can Quantitatively Predict the In Vivo Kinetics of Other CYP3A Substrates and Can Accurately Assess CYP3A Induction and Inhibition. *Mol Interv.* 5(3):151-3. 2005
109. Xu Y, Hashizume T, Shuhart M, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, Thummel KE. Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1 α ,25-dihydroxyvitamin D₃: Implications for drug-induced osteomalacia. *Mol. Pharmacol.* 69(1):56-65, 2006
110. Watkins PB, Seeff LB. Drug-induced liver injury: Summary of a single topic clinical research conference. *Hepatology* 43:618-31, 2006
111. Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins, PB. A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. *Am. J. of Clin. Nutr.* 83(5):1097-105, 2006
112. Lamba JK, Strom S, Venkataramanan R, Thummel KE, Lin YS, Liu W, Cheng C, Lamba JK, Watkins PB, Schuetz EG. MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. *Clin Pharmacol Ther.* 79(4):325-338, 2006
113. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, Thummel KE. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. *J Clin Invest* 116:1703-1712, 2006.
114. Lamba JK, Chen X, Lan LB, Kim JW, Wei Wand X, Relling MV, Kazuto Y, Watkins PB, Strom S, Sun D, Schuetz JD, Schuetz EG. Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans. *Pharmacogenet Genomics* 16(6):415-427, 2006
115. Watkins PB, Kaplowitz N, Slattery J T, Colucci SV, Colonnese C, Stewart P, Harris SC. High incidence of ALT elevations in healthy subjects receiving 4 grams acetaminophen daily: Results of a randomized, placebo controlled, single blind trial. *JAMA* 296(1):87-93, 2006.
116. Leslie EM, Watkins PB, Kim RB, Brouwer KL. Differential inhibition of rat and human Na⁺-dependent taurocholate co-transporting polypeptide (NTCP/SLC10A1) by bosentan: A mechanism for species differences in hepatotoxicity. *J. Pharmacol. Exp. Ther.* 321(3):1170-8, 2007.

117. Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE. Clinical pattern of zileuton-associated liver injury: Results of a 12-month study in patients with chronic asthma. *Drug Safety* 30(9):805-15, 2007.
118. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, Giacomini KM, Krauss R. Identifying genetic risk factors for serious adverse drug reactions: Current progress and future challenges. *Nature Drug Discovery Reviews*, 6(11):904-16, 2007
119. Isoherranen N, Ludington SR, Givens RC, Pusek SN, Dees EC, Blough D, Iwanaga K, Hawke RL, Schuetz EG, Watkins PB, Thummel KE, and Paine MF. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate dependent: an in vitro-in vivo evaluation. *Drug Metab Dispo.* 36(1):146-54, 2007.
120. Bushel, PR, Heinloth AN, Li J, Huang L, Chou, JW, Boorman, GA, Malarkey, DE, Houle CD, Ward S.M, Wilson RE, Fannin RD, Russo MW, Watkins PB, Tennant RW, and Paules RS. Blood gene expression signatures predict exposure levels. *Proc. Natl. Acad Sci.* 104(46):18211-6, 2007.
121. Olanow, CW, Watkins PB. Tolcapone: an efficacy and safety review. *Clin Neuropharmacol* 30(5):287-94, 2007.
122. Poonkuzhali B, Lamba J, Strom S, Sparreboom A, Thummel K, Watkins PB, and Erin G. Schuetz. Association of BCRP/ABCG2 Phenotypes with Novel promoter and intron1 SNPs. *Drug Metabo. Dispo.* 36(1):146-54, 2008
123. Chaluda PC, Vahdat HL, Sharp RR, Delosier TC, Watkins PB, Pusek SN, Blackshear PJ. The Environmental Polymorphism Registry: a DNA resource to study genetic susceptibility loci. *Human Genet.* 123(2):207-14, 2008.
124. Rochon J, Protiva P, Seeff LB, Fontana RJ, Liangpunsakul S, Watkins PB, Davern T, Mc Hutchinson JG. The reliability of the RUCAM for assessing causality in drug-induced liver injury. *Hepatology* 48(4):1175-83, 2008.
125. Chalasani N, Fontana R, Bonkovsky H, Watkins PB, Davern T, Serrano J, Yang H, Rochon J. Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States. *Gastroenterology* 135(6):1924-34, 2008.
126. Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, Watkins PB. Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. *Am J Clin Nutr.* 87(4):863-71, 2008
127. Watkins PB, Seligman PJ, Pears JS, Avigan MI, Senior JR. Using controlled clinical trials to learn more about acute drug-induced liver injury. *Hepatology* 48(5):1680-9, 2008
128. Hayashi, PH, Watkins, PB. Progress in our understanding of severe drug-induced liver injury. *Liver Transplantation* 15(7):675-6, July 2009.

129. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J. Rationale, Design and Conduct of the Drug Induced Liver Injury Network (DILIN) Prospective study. *Drug Safety* 32(1):55-68, 2009.
130. Zhou T, Chou J, Watkins PB, Kaufmann WK. Toxicogenomics: transcriptomic profiling for toxicology assessment. *EXS*, 99:325-66, 2009.
131. Harrill AH, Watkins PB, Su S, Ross PK, Harbourt DE, Stylianou IM, Boorman GA, Russo MW, Sackler RS, Harris SC, Smith PC, Tennant R, Bogue M, Paigen K, Harris C, Contractor T, Wiltshire T, Rusyn I, Threadgill DW. Mouse Model of the Human Population Reveals that Variants in CD44 Contribute to Acetaminophen-Induced Liver Injury in Humans. *Genome Research* (9):1507-15, 2009.
132. Winnike J H, Busby MG, Watkins PB, and O'Connell TM. Effects of a prolonged standardized diet on normalizing the human metabolome. *Am. J. Clin Nutr* 90:1-6, 2009.
133. Fannin RD, Russo M, O'Connell TM, Gerrish k, Winnike JH, Macdonald J, Newton J, Malik S, Sieber SO, Parker J, Shah R, Zhou T, Watkins PB, Paules RS. Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation. *Hepatology* 51(1):227-36, 2010
134. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, and Watkins PB. Use of Pharmaco-Metabonomics for Early Prediction of Acetaminophen-Induced Hepatotoxicity in Humans. *Clin Pharmacol Ther* 88(1):45-51, 2010.
135. Wetmore BA, Brees DJ, Singh R, Watkins PB, Andersen ME, Loy J, and Thomas RS. Quantitative Analyses and Transcriptomic Profiling of Circulating mRNAs as Biomarkers of Rat Liver Injury. *Hepatology* 52(6):2127-2139, 2010.
136. Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, Fontana RJ, Day CP, Chinnery PF. Common *POLG* genetic variants increase the risk of sodium valproate induced liver injury and failure. *Hepatology* 52(5):1791-1796, 2010.
137. Watkins PB, Desai M, Berkowitz S, Peters G, Horsmans Y, Larrey, D, and Maddrey W. Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH): Application of This Data Organization Tool to Phase III Clinical Trials of Rivaroxaban after Total Hip or Knee Replacement Surgery. *Drug Safety* 34 (3)243-252, 2011.
138. O'Connell, TM and Watkins, PB. The application of Metabolomics to predict drug-induced liver injury. *Clin Pharmacol Ther* 88(3):394-9, 2010.
139. Robertson, DG, Watkins, PB and Reily, MD. Metabolomics in toxicology: preclinical and clinical applications. *Toxicol Sci* 120(supp; 1):S146-S170, 2011.
140. Watkins. PB. Drug Safety sciences and the Bottleneck in Drug Development. *Clin Pharmacol Ther* 89(6):788-90, 2011.

141. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK; Spanish Dili Registry, EUDRAGENE, DILIN, DILIGEN, and International SAEC. Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury is influenced by Multiple HLA Class I and II Alleles. *Gastroenterology* 141(1):338-347, July 2011.
142. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case Definition and Phenotype Standardization in Drug-Induced Liver injury. *Clin Pharmacol Ther* 89(6):806-15, 2011.
143. Hertz DL, Walko CM, Bridges AS, Hull JH, Herendeen J, Rollins H, Watkins PB, Dees EC. Pilot Study of Rosiglitazone as an *in vivo* Probe of Paclitaxel Exposure. *Br J Clin Pharmacol* 74(1):197-200, Jul 2012.
144. Bell, LN, Vuppalanchi, R, Watkins, PB, Bonkovsky, HL, Serrano, J, Fontana, RJ, Wang, M, Rochon, J, Chalasani, N for the US Drug-Induced Liver Injury Network (DILIN) Research Group. Serum proteomic profiling in patients with drug-induced liver injury. *Aliment Pharmacol Ther* 35(5):600-612, Mar 2012.
145. Harril, AH, Roach, J, Fier, I, Eaddy, JS, Kurtz, CL, Antoine, DJ, Spencer, DM, Kishimoto, TK, Pisetsky, DS, Park, BK, Watkins, PB. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. *Clin Pharmacol Ther* 92(2): 214-20, Aug 2012.
146. Corsini, A, Ganey, P, Ju, C, Kaplowitz, N, Pessayre, D, Roth, R, Watkins, PB, Albassam, M, Liu, B, Stancic, S, Suter, L, Bortolini, M. Current Challenges and Controversies in Drug-Induced Liver Injury. *Drug Safety* (in press).
147. Urban, TJ, Goldstein, DB, Watkins, PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? *Pharmacogenomics* 13(7):735-8, May 2012.
148. Woodhead, JL, Howell, BA, Yang, Y, Harrill, AH, Clewell, HJ, Andersen, ME, Siler, SQ, Watkins, PB. An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury. *J Pharmacol Exp Ther* 342(2):529-40, Aug 2012.
149. Jeffries, RE, Gamcsik, M, Keshari, K, Padiaditakis, P, Tikunov, A, Young, G, Lee, H, Watkins, PB, Macdonald, J. Effect of oxygen concentration on viability and metabolism in a fluidized-bed bioartificial liver using ³¹P and ¹³C NMR spectroscopy. *Tissue Engineering* (Epub ahead of print 28 Sept 2012).
150. Winnike, JH, Padiaditakis, P, Wolak, J, McClelland, R, Watkins, PB, Macdonald, JM. Stable Isotope Resolved Metabolomics of Primary Human Hepatocytes Reveals a Stressed Phenotype. In Press, *Metabolomics*.

151. Urban, TJ, Shen, Y, Stolz, A, Chalasani, N, Fontana, RJ, Rochon, J, Dongliang, G, Shianna, KV, Daly, AK, Lucena, MI, Nelson, MR, Molokhia, M, Aithal, GP, Floratos, A, Serrano, J, Bonkovsky, H, Davern, TJ, Lee, WM, Navarro, VJ, Talwalkar, JA, Goldstein, DB, Watkins, PB, on behalf of the Drug Induced Liver Injury Network and the International Serious Adverse Events Consortium. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. *Pharmacogenetics and Genomics* (in press).
152. Harrill, AH, DeSmet, KD, Wolf, KK, Bridges, AS, Eaddy, JC, Kurtz, CL, Hall, JE, Paine, MF, Tidwell, RR, Watkins, PB. A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. *Toxicol Sciences* (E pub 14 Sept 2012).
153. Howell, BA, Yang, Y, Kumar, R, Woodhead, JL, Harrill, AH, Clewell, HJ, Andersen, ME, Siler, SQ, Watkins, PB. *In vitro* to *in vivo* extrapolation and species response comparisons for drug induced liver injury (DILI) using DILIsym™, a mechanistic, mathematical model of DILI. *J Pharmacokinet Pharmacodyn* 39(5): 527-41, Oct 2012.
154. Zhang, L, Bushel, PR, Chou, J, Zhou, T, Watkins, PB. Identification of Identical Transcript Changes in Liver and Whole Blood during Acetaminophen Toxicity. *Front Genet* (E pub 4 Sept 2012).
155. Griffin, LM, Watkins, PB, Perry, CH, St Claire, RL, Brouwer, KL. Combination Lopinavir and Ritonavir Alter Exogenous and Endogenous Bile Acid Disposition in Sandwich-Cultured Rat Hepatocytes. *Drug Metab Dispos* 2012 (Epub ahead of print).
156. Bhattacharya, S, Shoda, LK, Zhang, Q, Woods, C, Howell, BA, Siler, SQ, Woodhead, JL, Yang, Y, McMullen, P, Watkins, PB, Andersen, ME. Modeling drug- and chemical- induced hepatotoxicity with systems biology approaches. *Frontiers in Systems Biology* 2012 (in press).

Non-peer reviewed journals - None

Book Chapters and Reviews

1. Watkins, P.B., Bond, J., Guzelian, P.S.: "Degradation of the Hepatic Cytochromes P-450". In: *Critical Reviews in Biochemistry, The Mammalian Cytochromes P-450*, ed. F.P. Guengerich (CRC Press, 1987), Ch. 6, 173.
2. Watkins, P.B.: "The role of cytochromes P-450 in drug metabolism and hepatotoxicity." In: *Seminars in Liver Diseases, Recent Advances in Drug Metabolism and Hepatotoxicity*, ed. N. Kaplowitz 1990; 10 (4):235-250.
3. Watkins, P.B.: *Cytochromes P-450 and drug metabolism. View Points in Digestive Diseases* 1990; 22(3):7-12.

4. Watkins, P.B.: "Pharmacology of the Gut." In: Textbook of Gastroenterology, ed. T. Yamada (Lippincott, 1991), 518-531.
5. Watkins, P.B.: In vivo and in vitro characterization of P450III_A. In: Methods in Enzymology, The Cytochromes P-450. (Eds) Waterman, M. and Johnson, E., 116-132. (1992).
6. Watkins, P.B. Drug metabolism by cytochromes P450 in liver and small bowel. In Gastroenterology Clinics of North America (ED) William Stetson. 1992; 21(3):511-525.
7. Watkins, P.B. Gastrointestinal Toxicology. In: Textbook of Gastroenterology, second edition. (Ed.) T. Yamada (Lipincott), p.p. 596-606. 1995.
8. Fontana, R.J., Watkins, P.B., Genetic Predisposition to Drug Induced Liver Disease. Gastroenterology Clinics of North America (ED) James Lewis. 24:4;811-838, 1995.
9. Watkins, P.B. In vivo probes of cytochrome P450 activity: Prediction of drug-drug interactions and susceptibility to adverse drug reactions. Drug Information Journal, in press.
10. Watkins, P.B. Mucosal Transformations. In Comprehensive Toxicology, Eds. G. Sipes, C. McQueen, and J. Gandolfi. Elsevier Press, vol. 9, 549-558,1997
11. Lumeng, L, Kaplowitz, N. Watkins, P.B., Drug Induced Liver Disease. In A Research Agenda for 25 Million Americans: Research goals and strategies to treat, prevent, and conquer liver disease. The American Liver Foundation, pg.45-49, 1995.
12. Watkins, P.B. The use of the erythromycin breath test in drug development. In Pharmacogenetics: Bridging the gap between basic science and clinical application. J. Schlegel, Ed. IBC Library Series, Pg 2.1.1 - 2.1.19,1996.
13. Watkins, P.B. The barrier function of CYP3A4 and p-glycoprotein in the intestine. Advanced Drug Delivery Reviews, K.Thummel ed 27:161-170, 1997
14. Watkins, P.B.: "Toxicology of the Gut." In: Textbook of Gastroenterology, ed. T. Yamada Third Edition, (Lippincott-Raven, 1998).
15. Watkins,P.B. "Mechanisms of drug induced liver disease" In:Schiff's Diseases of the Liver, Schiff,E.R., Sorrell, M.F., Maddrey, W.C. (Lippincott-Raven) pp 1065 - 1082,1998.
16. Watkins, PB, Approaches to studying the role of transporters in drug interactions in man. In: Variability in Human Drug Response, G.T. Tucker Ed. (Excerpta Medica). Pp. 55-63, 1999.
17. Wrighton, S.A., Schuetz, E.G., Thummel, K.E., Shen, D.D., Korzekwa, K.R., Watkins, P.B., The human CYP3A subfamily: Practical considerations. Drug Metabolism Reviews 32(3-4):339-361, 2000.

18. Watkins, P.B. Role of cytochromes P450 in drug induced liver disease. In Drug Induced Liver Disease, Neil Kaplowitz and Laurie Deleve, eds, Lippincott, 2004
19. Watkins, P.B.: "Drug Metabolism." In: Textbook of Gastroenterology, ed. T. Yamada Third Edition, (Lippincott-Williams & Wilkins) pp592-602, 2003.
20. Watkins,P.B. "Mechanisms of drug induced liver disease" In: Schiff's Diseases of the Liver, Schiff,E.R., Sorrell, M.F., Maddrey, W.C. Ninth Edition (Lippincott - Williams and Wilkins) pp1059-1129, 2003.
21. Schuetz E G, Relling M V, Kishi. Yang S W S. Das, P. Chen, E. H. Cook, G. L. Rosner, C. H. Pui, J. G. Blanco, M. J. Edick, M. L. Hancock, N. J. Winick, T. Dervieux, M. D. Amylon, R. O. Bash, F. G. Behm, B. M. Camitta, S. C. Raimondi, B. C. G oh, S. C. Lee, L. Z. Wang, L. Fan, J. Y. Guo, J. Lamba, R. Lim, H. L. Lim, A. B. Ong, H. S. Lee, P. Kuehl, J. Zhang, Y. Lin, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, P. Maurel, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel and M. S. Boguski. "PharmGKB Update: CYP3A5, Cytochrome P450, Family 3, Subfamily A, Polypeptide 5". Pharmacological Reviews 56:159- 168, 2004.
22. Watkins, P.B. "Drug Metabolism." In: Textbook of Gastroenterology, ed. T. Yamada Fourth Edition, (Lippincott-Williams & Wilkins). In press.
23. Russo M and Watkins PB, Genetic Susceptibility to Drug-Induced Liver Disease, in Drug-Induced Liver Disease, Second Edition Neil Kaplowitz and Laurie Deleve, eds, 2007, Culinary and Hospitality Industry Publications Services
24. Watkins,P.B. 10th edition. "Mechanisms of drug induced liver disease" In: Schiff's Diseases of the Liver, Schiff,E.R., Sorrell, M.F., Maddrey, W.C. Lippincott - Williams and Wilkins pp1059-1129, 2008.
25. Watkins PB. Seminars in Liver Diseases, Biomarkers for the diagnosis and management of drug-induced liver injury. Semin Liver Dis. 2009 24(9):393-399.
26. Wolf KK, Watkins PB, and Paine MF. Metabolic barrier of the GI tract. In: Comprehensive Toxicology: Toxicology of the Gastrointestinal Tract. Eds. G. Sipes, C. McQueen, and J. Gandolfi. Elsevier Press.
27. Watkins PB. Biomarkers for Drug Induced Liver Injury. Biomarkers. In press.
28. Watkins,P.B. 11^h edition. "Mechanisms of drug induced liver disease" In: Schiff's Diseases of the Liver, Schiff, E.R., Sorrell, M.F., Maddrey, W.C. Lippincott - Williams and Wilkins. In press.

Abstracts – Available on request